<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006026</article-id><article-id pub-id-type="pmc">PMC11859338</article-id><article-id pub-id-type="doi">10.3390/ph18020211</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00211</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Thermodynamic and Structural Characterization of a Mechanochemically Synthesized Pyrazinamide&#x02013;Acetylsalicylic&#x02013;Acid Eutectic Mixture</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Queiroz</surname><given-names>Lu&#x000ed;s H. S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-18-00211" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4810-0479</contrib-id><name><surname>Lage</surname><given-names>Mateus R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00211" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3156-8673</contrib-id><name><surname>dos Santos</surname><given-names>Clenilton C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceuticals-18-00211" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0294-5596</contrib-id><name><surname>Sarragu&#x000e7;a</surname><given-names>Mafalda C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-pharmaceuticals-18-00211" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5832-5623</contrib-id><name><surname>Ribeiro</surname><given-names>Paulo R. S.</given-names></name><xref rid="af1-pharmaceuticals-18-00211" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00211" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Birsa</surname><given-names>Mihail Lucian</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00211"><label>1</label>Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Ci&#x000ea;ncia dos Materiais (PPGCM), Centro de Ci&#x000ea;ncias de Imperatriz (CCIM), Universidade Federal do Maranh&#x000e3;o (UFMA), Imperatriz 65900-410, Maranh&#x000e3;o, Brazil; <email>henrique_queiroz26@hotmail.com</email> (L.H.S.Q.); <email>mateus.lage@ufma.br</email> (M.R.L.)</aff><aff id="af2-pharmaceuticals-18-00211"><label>2</label>Laborat&#x000f3;rio de Espectroscopia Vibracional e Imped&#x000e2;ncia (LEVI), Departamento de F&#x000ed;sica, Universidade Federal do Maranh&#x000e3;o (UFMA), S&#x000e3;o Lu&#x000ed;s 65085-580, Maranh&#x000e3;o, Brazil; <email>cleniltoncs@gmail.com</email></aff><aff id="af3-pharmaceuticals-18-00211"><label>3</label>LAQV/REQUIMTE, Department of Chemical Sciences, Laboratory of Applied Chemistry, Faculty of Pharmacy, Porto University, 4050-313 Porto, Portugal; <email>mafalda.cruz@ff.up.pt</email></aff><author-notes><corresp id="c1-pharmaceuticals-18-00211"><label>*</label>Correspondence: <email>paulo.rsr@ufma.br</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>211</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>30</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> This study aims to develop a sustainable and environmentally friendly drug delivery system by synthesizing a novel drug&#x02013;drug eutectic mixture (DDEM) of acetylsalicylic acid (ASA) and pyrazinamide (PZA) using a green and efficient mechanochemical approach. <bold>Methods:</bold> The DDEM was characterized using various techniques, including differential scanning calorimetry (DSC), thermogravimetry and differential thermal analysis (TG-DTA), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR), and Raman spectroscopy. Binary phase diagrams and Tammann&#x02019;s triangle analysis determined the eutectic point. Density functional theory (DFT) calculations were performed on the starting compounds. The new system was evaluated for aqueous solubility, dissolution, and hygroscopicity. <bold>Results:</bold> A V-shaped binary phase diagram indicated the formation of a DDEM with a 2:1 molar ratio of ASA to PZA. A positive mixing enthalpy suggested a quasi-eutectic structure. The solubility of ASA and PZA increased by 61.5% and 85.8%, respectively, in the DDEM compared to the pure drugs. <bold>Conclusions:</bold> These findings highlight the potential of DDEMs to enhance drug properties and delivery. The synergistic interaction between ASA and PZA in the eutectic mixture may further improve therapeutic efficacy, warranting further investigation.</p></abstract><kwd-group><kwd>acetylsalicylic acid (ASA)</kwd><kwd>pyrazinamide (PZA)</kwd><kwd>drug&#x02013;drug eutectic mixture (DDEM)</kwd><kwd>DFT calculations</kwd><kwd>green chemistry</kwd><kwd>mechanochemistry</kwd><kwd>tuberculosis</kwd></kwd-group><funding-group><award-group><funding-source>PT national funds</funding-source><award-id>UID/50006</award-id></award-group><award-group><funding-source>Individual Call to Scientific Employment Stimulus</funding-source></award-group><award-group><funding-source>FAPEMA</funding-source><award-id>INFRA-02050-21</award-id></award-group><award-group><funding-source>CNPq</funding-source><award-id>310127/2023-8</award-id></award-group><funding-statement>This work received financial support from the PT national funds (FCT/MECI, Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia and Minist&#x000e9;rio da Educa&#x000e7;&#x000e3;o, Ci&#x000ea;ncia e Inova&#x000e7;&#x000e3;o) through the project UID/50006&#x02014;Laborat&#x000f3;rio Associado para a Qu&#x000ed;mica Verde&#x02014;Tecnologias e Processos Limpos. M. C. Sarragu&#x000e7;a thanks FCT for funding through the Individual Call to Scientific Employment Stimulus DOI 10.54499/2022.01388.CEECIND/CP1724/CT0003. C. C. Santos acknowledges the support of FAPEMA (Grant INFRA-02050-21) and CNPq (Grant N&#x000b0; 310127/2023-8).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00211"><title>1. Introduction</title><p>Eutectic pharmaceutical systems have emerged as a promising approach to enhance the physicochemical properties of drugs [<xref rid="B1-pharmaceuticals-18-00211" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>]. A eutectic mixture (EM) is a combination of at least two solid components that undergo a phase transition into a liquid at a specific temperature, called the eutectic point. Substances in EMs are not isomorphous, and the components have a heterogeneous separation. These components are immiscible in the solid state, and there is no evidence of intermolecular interactions [<xref rid="B3-pharmaceuticals-18-00211" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00211" ref-type="bibr">4</xref>]. Unlike EMs, cocrystals, salts, and coamorphous systems exhibit intermolecular interactions, established between the drug and the coformer or another drug [<xref rid="B5-pharmaceuticals-18-00211" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00211" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00211" ref-type="bibr">7</xref>]. Drug&#x02013;drug eutectic mixtures (DDEMs) are EMs composed of two or more drugs [<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>,<xref rid="B8-pharmaceuticals-18-00211" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-18-00211" ref-type="bibr">9</xref>].</p><p>EMs can be prepared by various methods, including solvent evaporation, cooling, electrospray deposition, and mechanochemical techniques. Mechanochemical methods, such as neat grinding and liquid-assisted grinding (LAG), offer several advantages for the preparation of EMs. These methods are solvent-free or use minimal amounts of solvent, making them environmentally friendly and cost-effective [<xref rid="B10-pharmaceuticals-18-00211" ref-type="bibr">10</xref>]. Additionally, mechanochemical synthesis can be rapid, often requiring shorter reaction times compared to traditional solution-based methods [<xref rid="B11-pharmaceuticals-18-00211" ref-type="bibr">11</xref>]. This technique can also be applied to a wide range of compounds, including those with poor solubility, and can lead to the formation of metastable phases and amorphous materials, which can enhance drug dissolution and bioavailability. LAG involves the addition of a small volume of organic solvent to the solid starting materials. The milling process generates energy, promoting weak intermolecular interactions between the components. The solvent facilitates these interactions. After the reaction, the solvent evaporates completely, leaving no residual material. LAG offers advantages over neat grinding, such as reduced processing time and more efficient molecular interactions [<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>,<xref rid="B12-pharmaceuticals-18-00211" ref-type="bibr">12</xref>].</p><p><italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">M. tuberculosis</italic>), the causative agent of tuberculosis (TB), a chronic infectious disease, continues to pose a significant global health threat. In 2021, it was the second deadliest infectious disease after SARS-CoV-2, with 10 million cases and over 1 million deaths [<xref rid="B13-pharmaceuticals-18-00211" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-18-00211" ref-type="bibr">14</xref>]. Pyrazinamide (PZA), shown in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S1a</xref>, is an essential first-line anti-tuberculosis medication. It is used in conjunction with rifampicin, isoniazid, and ethambutol to treat tuberculosis, a combination often referred to as fixed-dose combinations [<xref rid="B15-pharmaceuticals-18-00211" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00211" ref-type="bibr">16</xref>]. This drug significantly shortens treatment duration by three months [<xref rid="B14-pharmaceuticals-18-00211" ref-type="bibr">14</xref>]; however, its efficacy is challenged by increasing resistance [<xref rid="B17-pharmaceuticals-18-00211" ref-type="bibr">17</xref>]. PZA, pyrazine-2-carboxamide, is a prodrug derived from nicotinamide and it is converted into its active pyrazinoic acid (POA) in an acidic environment [<xref rid="B18-pharmaceuticals-18-00211" ref-type="bibr">18</xref>]. The primary mechanism for POA (pKa = 2.9) [<xref rid="B19-pharmaceuticals-18-00211" ref-type="bibr">19</xref>] to exit the cell in <italic toggle="yes">M. tuberculosis</italic> is passive diffusion, with minimal contribution from efflux pumps. POA undergoes protonation to form HPOA, a molecule that readily crosses the plasma membrane. This can lead to cytoplasmic acidification, potentially inhibiting the activity of essential enzymes [<xref rid="B16-pharmaceuticals-18-00211" ref-type="bibr">16</xref>]. PZA is a water-soluble drug (15 mg.mL<sup>&#x02212;1</sup>) with moderate permeability, classified as a BCS class III drug in the biopharmaceutical classification system [<xref rid="B20-pharmaceuticals-18-00211" ref-type="bibr">20</xref>]. This extremely weak base (pKa = 0.5) [<xref rid="B19-pharmaceuticals-18-00211" ref-type="bibr">19</xref>] has a melting range of 189&#x02013;191 &#x000b0;C and exists in four polymorphic forms (&#x003b1;, &#x003b2;, &#x003b3;, and &#x003b4;) [<xref rid="B21-pharmaceuticals-18-00211" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00211" ref-type="bibr">22</xref>]. Form <italic toggle="yes">&#x003b1;</italic> is the most stable and commercially available form [<xref rid="B20-pharmaceuticals-18-00211" ref-type="bibr">20</xref>,<xref rid="B23-pharmaceuticals-18-00211" ref-type="bibr">23</xref>], while the other forms are metastable and transit to form &#x003b1; at room temperature.</p><p>Cocrystals of PZA have been reported with various acids, including 2,5-dihydroxybenzoic acid [<xref rid="B24-pharmaceuticals-18-00211" ref-type="bibr">24</xref>], p-aminobenzoic acid [<xref rid="B25-pharmaceuticals-18-00211" ref-type="bibr">25</xref>], p-toluenesulfonic, ferulic acid [<xref rid="B26-pharmaceuticals-18-00211" ref-type="bibr">26</xref>], oxalic acid [<xref rid="B27-pharmaceuticals-18-00211" ref-type="bibr">27</xref>], among others [<xref rid="B28-pharmaceuticals-18-00211" ref-type="bibr">28</xref>]. PZA has also formed cocrystals with other drugs, such as entacapone [<xref rid="B29-pharmaceuticals-18-00211" ref-type="bibr">29</xref>], diflunisal [<xref rid="B30-pharmaceuticals-18-00211" ref-type="bibr">30</xref>], pyrogallol [<xref rid="B31-pharmaceuticals-18-00211" ref-type="bibr">31</xref>], and theophylline [<xref rid="B32-pharmaceuticals-18-00211" ref-type="bibr">32</xref>]. Eutectic mixtures of PZA have been reported with saccharin, salicylic acid, cinnamic acid, nicotinic acid, isonicotinic acid [<xref rid="B28-pharmaceuticals-18-00211" ref-type="bibr">28</xref>], and isoniazid [<xref rid="B33-pharmaceuticals-18-00211" ref-type="bibr">33</xref>].</p><p>Acetylsalicylic acid (ASA), depicted in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S1b</xref>, also known as 2-acetyloxybenzoic acid, is a non-steroidal anti-inflammatory drug (NSAID). This weak acid has a reported pKa value of 3.50 and undergoes thermal decomposition after melting at approximately 140 &#x000b0;C [<xref rid="B34-pharmaceuticals-18-00211" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00211" ref-type="bibr">35</xref>]. ASA exhibits pH-dependent solubility characteristics, increasing as the pH rises above the p<italic toggle="yes">K</italic>a. It is classified as a BSC class I due to its high aqueous solubility (3.33 mg.mL<sup>&#x02212;1</sup>) and membrane permeability [<xref rid="B21-pharmaceuticals-18-00211" ref-type="bibr">21</xref>,<xref rid="B35-pharmaceuticals-18-00211" ref-type="bibr">35</xref>]. ASA exists in three polymorphic forms: form I, form II, and form III [<xref rid="B36-pharmaceuticals-18-00211" ref-type="bibr">36</xref>]. Studies have explored the formulation of solid dispersions of ASA with other drugs and coformers [<xref rid="B34-pharmaceuticals-18-00211" ref-type="bibr">34</xref>,<xref rid="B37-pharmaceuticals-18-00211" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00211" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00211" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00211" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00211" ref-type="bibr">41</xref>].</p><p>Previous studies have shown that ASA can enhance the efficacy of PZA in reducing bacterial load [<xref rid="B42-pharmaceuticals-18-00211" ref-type="bibr">42</xref>] in TB infections [<xref rid="B43-pharmaceuticals-18-00211" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-18-00211" ref-type="bibr">44</xref>]. Chen et al. [<xref rid="B45-pharmaceuticals-18-00211" ref-type="bibr">45</xref>] demonstrated that co-administration of weak acids, including salicylic acid, with PZA resulted in reduced bacterial loads of <italic toggle="yes">M. tuberculosis</italic> in vitro. Furthermore, Byrne et al. [<xref rid="B42-pharmaceuticals-18-00211" ref-type="bibr">42</xref>] showed that the combination of PZA with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and ASA, enhanced PZA&#x02019;s potency in a mouse model of TB infection. In the mouse model, PZA alone reduced bacterial counts in the lungs from 6.9 &#x000b1; 0.1 log10 CFU to 5.6 &#x000b1; 0.5 log10 CFU. The combination of PZA with ASA further reduced lung bacterial counts to 5.0 &#x000b1; 0.3 log10 CFU, representing an approximate 0.6 log10 CFU reduction compared to PZA alone. In the spleen, PZA alone reduced bacterial counts from 4.5 &#x000b1; 0.2 log10 CFU to 2.7 &#x000b1; 1.1 log10 CFU. While the ASA and PZA combination resulted in complete bacterial clearance in the spleen of two out of five mice, the overall reduction in spleen bacterial counts was not statistically significant compared to PZA alone. Additionally, PZA therapy can cause common side effects, such as nongouty polyarthralgias, which generally do not occur during the initial phase of treatment. Non-steroidal anti-inflammatory drugs, such as ASA, are generally effective in alleviating the pain associated with this adverse effect [<xref rid="B46-pharmaceuticals-18-00211" ref-type="bibr">46</xref>]. Current PZA formulations may have limitations, such as potential drug&#x02013;drug interactions and gastrointestinal side effects, which can impact patient adherence and overall treatment outcomes. The emergence of drug-resistant strains of <italic toggle="yes">M. tuberculosis</italic> further underscores the need for improved treatment strategies. These findings, coupled with the potential to mitigate PZA-related side effects, suggest that the combination of ASA and PZA in a drug delivery system, such as a DDEM, could significantly enhance the therapeutic efficacy of both drugs, particularly in the treatment of drug-resistant TB.</p><p>This study employed the green and efficient liquid-assisted LAG technique to prepare a novel DDEM of PZA and ASA. The eutectic composition was determined using binary phase diagrams and Tammann&#x02019;s triangle analysis. A comprehensive solid-state characterization, including differential scanning calorimetry (DSC), thermogravimetry and differential thermal analysis (TG-DTA), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR), and Raman spectroscopy, was performed. To understand molecular interactions and the energy landscape, density functional theory (DFT) calculations were performed. Additionally, the aqueous solubility and dissolution profiles of the DDEM were determined.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00211"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00211"><title>2.1. Thermal Analysis</title><p>DSC was used to study the eutectic composition [<xref rid="B47-pharmaceuticals-18-00211" ref-type="bibr">47</xref>]. ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, and mixtures prepared by the LAG method with molar ratios of ASA ranging from 0.17 to 0.83 were analyzed. <xref rid="pharmaceuticals-18-00211-f001" ref-type="fig">Figure 1</xref> illustrates the resulting DSC curves, while <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S1 (Supporting Information)</xref> summarizes the key thermal events.</p><p>The DSC thermograms of ASA and PZA revealed the following: ASA exhibits a melting point of 140.8 &#x000b0;C, with an enthalpy of fusion (&#x00394;H<italic toggle="yes"><sub>f</sub><sub>us</sub></italic>) of 41.33 kJ.mol<sup>&#x02212;1</sup> [<xref rid="B37-pharmaceuticals-18-00211" ref-type="bibr">37</xref>]. PZA underwent a solid&#x02013;solid phase transition (form &#x003b1; &#x02192; form &#x003b3;) at 152.0 &#x000b0;C with a transition enthalpy (&#x00394;H<italic toggle="yes"><sub>trs</sub></italic>) of 1.52 kJ.mol<sup>&#x02212;1</sup>, followed by a melting point at 189.5 &#x000b0;C (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> = 26.69 kJ.mol<sup>&#x02212;1</sup>) [<xref rid="B22-pharmaceuticals-18-00211" ref-type="bibr">22</xref>]. The physical mixture (PM) displayed a melting point of 115.3 &#x000b0;C (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S2, Supporting Information)</xref>.</p><p>The phase diagram plots the melting temperature against the mole fraction of one component. The solidus point represents the T<italic toggle="yes"><sub>fus</sub></italic> of the eutectic mixture, while the liquidus point corresponds to the excess component. The V-shape pattern in the diagram indicates the eutectic point, characterized by its minimum melting temperature and specific molar ratio [<xref rid="B48-pharmaceuticals-18-00211" ref-type="bibr">48</xref>]. The &#x00394;H<italic toggle="yes"><sub>fus</sub></italic> was used to determine the eutectic stoichiometry across the range of mixtures. As the relative proportions of the components vary, the &#x00394;H<italic toggle="yes"><sub>fus</sub></italic> value increases to its maximum at the eutectic composition and then decreases. This maximum value corresponds to the eutectic point, indicating the optimal composition for the lowest melting point [<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>,<xref rid="B49-pharmaceuticals-18-00211" ref-type="bibr">49</xref>].</p><p>A binary phase diagram and a Tammann&#x02019;s triangle were constructed using the mole fraction of ASA as the independent variable. The eutectic point was determined from these graphical representations. The experimental data used to construct these diagrams are presented in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S2</xref>. The DSC curves for ASA-PZA mixtures (<xref rid="pharmaceuticals-18-00211-f001" ref-type="fig">Figure 1</xref>) exhibited a common melting point range of 111&#x02013;114 &#x000b0;C. The congruent melt in the phase diagram and the inflection point in Tammann&#x02019;s triangle suggest a eutectic stoichiometry of 2:1 (&#x003c7;<sub>ASA</sub> = 0.67). This stoichiometry is further supported by the V-shape of the phase diagram, which arises from the significantly lower melting point of the eutectic mixture (T<italic toggle="yes"><sub>fus</sub></italic> = 114.2 &#x000b0;C) compared to the pure components (ASA<sub>LAG</sub>: T<italic toggle="yes"><sub>fus</sub></italic> = 140.8 &#x000b0;C; PZA<sub>LAG</sub>: T<italic toggle="yes"><sub>fus</sub></italic> = 189.5 &#x000b0;C). Based on these findings, the ASA-PZA (2:1) mixture (DDEM) was selected for further characterization and evaluation.</p><p>The theoretical phase diagram, constructed using the values in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S3 (Supporting Information)</xref>, predicted the formation of a eutectic mixture at &#x003c7;&#x02019;<sub>ASA</sub> = 0.63 (<xref rid="pharmaceuticals-18-00211-f002" ref-type="fig">Figure 2</xref>). The slight discrepancy between the theoretical and experimental eutectic compositions can be attributed to factors such as limitations in the theoretical model and the influence of intermolecular interactions.</p><p>The nondimensional entropy of fusion (&#x00394;S<italic toggle="yes"><sub>fus</sub></italic><sup>0</sup>) for pure components and DDEM are presented in <xref rid="pharmaceuticals-18-00211-t001" ref-type="table">Table 1</xref>. The entropy of fusion (&#x00394;S<italic toggle="yes"><sub>fus</sub></italic>) was calculated using the enthalpy of fusion and melting temperature [<xref rid="B8-pharmaceuticals-18-00211" ref-type="bibr">8</xref>,<xref rid="B50-pharmaceuticals-18-00211" ref-type="bibr">50</xref>].</p><p>Simple binary eutectic systems can be classified based on the entropies of fusion of their individual components. If one component has a low entropy of fusion (&#x00394;S<italic toggle="yes"><sub>fus</sub></italic><sup>0</sup> &#x0003c; 2), the eutectic crystallization exhibits &#x0201c;couple growth&#x0201d;, where both components grow simultaneously in a coordinated manner, resulting in a well-defined microstructure. Conversely, if both components have high entropies of fusion, they grow independently, forming a simple physical mixture of anisotropic/faceted crystals [<xref rid="B51-pharmaceuticals-18-00211" ref-type="bibr">51</xref>].</p><p>The starting materials ASA<sub>LAG</sub> and PZA<sub>LAG</sub> have &#x00394;S<italic toggle="yes"><sub>fus</sub></italic><sup>0</sup> values greater than 2, indicating that the resulting compound is a simple mixture. The DDEM also has &#x00394;S<italic toggle="yes"><sub>fus</sub></italic><sup>0</sup> &#x0003e; 2, suggesting a higher nondimensional entropy of fusion [<xref rid="B52-pharmaceuticals-18-00211" ref-type="bibr">52</xref>]. This implies that the &#x00394;S<italic toggle="yes"><sub>fus</sub></italic> of the DDEM is greater than that of the crystalline ASA and PZA. This elevated thermodynamic state of the DDEM may be attributed to significant micronization [<xref rid="B8-pharmaceuticals-18-00211" ref-type="bibr">8</xref>], a process that reduces particle size and increases the surface area of a substance. This increased surface area can lead to enhanced molecular mobility and weaker intermolecular interactions within the DDEM, resulting in a higher entropy of fusion. This higher entropy state can contribute to the formation of a more disordered, quasi-eutectic structure.</p><p>Thermochemical studies indicate that the structural arrangement within a eutectic melt is dependent on the sign and magnitude of the mixing enthalpy. Three possible structures include quasieutectic (<inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup><mml:mi>H</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> &#x0003e; 0), clustering of molecules (<inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup><mml:mi>H</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> &#x0003c; 0), and molecular solutions (<inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup><mml:mi>H</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> = 0) [<xref rid="B53-pharmaceuticals-18-00211" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-18-00211" ref-type="bibr">54</xref>]. For the ASA-PZA system, the experimentally determined mixing enthalpy (<inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) was 119.21 kJ.mol<sup>&#x02212;1</sup>, while the calculated value (<inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) was 37.60 kJ.mol<sup>&#x02212;1</sup>. The positive difference that corresponds to the value of the mixing enthalpy (<inline-formula><mml:math id="mm6" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup><mml:mi>H</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> = 81.61 kJ.mol<sup>&#x02212;1</sup>), which indicates weak intermolecular interactions between the components in the melt, is indicative of a quasi-eutectic structure in the binary eutectic melt.</p><p>The TG/DTG-DTA curves of ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, DDEM, and PM are presented in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S3 (Supporting Information)</xref>, while the corresponding thermal parameters are summarized in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Tables S4 and S5 (Supporting Information)</xref>.</p><p>This technique provides insights into the thermal stability and decomposition behavior of the samples. ASA<sub>LAG</sub> exhibits thermal stability up to 135 &#x000b0;C, followed by a two-stage decomposition process: 135&#x02013;257 &#x000b0;C (mass loss, &#x00394;<italic toggle="yes">m</italic> = 49.5%) and 257&#x02013;360 &#x000b0;C (&#x00394;<italic toggle="yes">m</italic> = 47.7%). The DTA reveals a sharp endothermic peak at 139.0 &#x000b0;C, corresponding to the melting point (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> = 204.33 kJ.mol<sup>&#x02212;1</sup>). The two additional endothermic peaks at 163.5 &#x000b0;C and 346.6 &#x000b0;C correspond to the decomposition processes [<xref rid="B40-pharmaceuticals-18-00211" ref-type="bibr">40</xref>]. PZA<sub>LAG</sub> is thermally stable up to 134 &#x000b0;C, followed by sublimation (134&#x02013;188 &#x000b0;C, &#x00394;<italic toggle="yes">m</italic> = 30.5%) and evaporation (188&#x02013;226 &#x000b0;C, &#x00394;<italic toggle="yes">m</italic> = 67.9%) processes. The DTA curve shows a solid-solid phase transition (form &#x003b1; &#x02192; form &#x003b3;) at 152.1 &#x000b0;C (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> = 3.67 kJ.mol<sup>&#x02212;1</sup>), a melting point at 188.6 &#x000b0;C (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> = 80.96 kJ.mol<sup>&#x02212;1</sup>), and a final decomposition step at 203.5 &#x000b0;C [<xref rid="B22-pharmaceuticals-18-00211" ref-type="bibr">22</xref>]. The DDEM is thermally stable up to 134 &#x000b0;C where it decomposes in two stages: 134&#x02013;252 &#x000b0;C (&#x00394;<italic toggle="yes">m</italic> = 54.1%) and 252&#x02013;363 &#x000b0;C (&#x00394;<italic toggle="yes">m</italic> = 42.4%). The DTA curve shows a low melting point at 113.6 &#x000b0;C (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> = 571.76 kJ.mol<sup>&#x02212;1</sup>) followed by decomposition at 152.1 &#x000b0;C and 294.8 &#x000b0;C. The PM exhibits similar thermal behavior, with a melting point at 115.9 &#x000b0;C. While the melting point decreased in the PM, the enthalpy of fusion increased (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S2</xref>, <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S1</xref>), indicating the effectiveness of the preparation method.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00211"><title>2.2. Structural Characterization and Molecular Interactions</title><p>PXRD is a powerful technique for distinguishing eutectic mixtures from cocrystals/salts. The absence of new diffraction peaks in the PXRD pattern of a eutectic mixture indicates the absence of a new crystalline phase, confirming the molecular distribution of the individual components within the crystal lattice. In contrast, cocrystals/salts formation leads to significant changes in the diffractogram profile [<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>].</p><p>FT-IR and Raman spectroscopy are complementary techniques that analyse molecular vibrations, providing insights into structure and interactions. However, these techniques have limitations in quantifying weak intermolecular interactions, which are crucial for a comprehensive understanding of the system. Therefore, a combination of PXRD and spectroscopic techniques is essential for elucidating the crystal lattice interactions [<xref rid="B55-pharmaceuticals-18-00211" ref-type="bibr">55</xref>].</p><p>PXRD patterns of ASA<sub>LAG</sub>, PZA<sub>LAG</sub> and various ASA-PZA molar ratios are shown in <xref rid="pharmaceuticals-18-00211-f003" ref-type="fig">Figure 3</xref>. Comparison with CCDC diffractograms confirmed that grinding did not alter the polymorphic forms of ASA and PZA, as evidenced by the Rietveld refinement quality parameters (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S4, Supporting Information</xref>).</p><p>ASA<sub>LAG</sub> shows PXRD peaks at 7.7&#x000b0;, 13.9&#x000b0;, 20.6&#x000b0;, 22.6&#x000b0;, 23.1&#x000b0; and 27.0&#x000b0; (2<italic toggle="yes">&#x003b8;</italic>), consistent with form I (REFCODE: ACSALA29) [<xref rid="B56-pharmaceuticals-18-00211" ref-type="bibr">56</xref>]. Rietveld refinement yielded R<sub>wp</sub> = 10.2% and S = 2.2. PZA<sub>LAG</sub> exhibits peaks at 7.8&#x000b0;, 13.7&#x000b0;, 15. 3&#x000b0;, 15.6&#x000b0;, 17.6&#x000b0;, 20.5&#x000b0;, 23.7&#x000b0;, 24.4&#x000b0;, 26.3&#x000b0;, and 27.4&#x000b0; (2<italic toggle="yes">&#x003b8;</italic>), corresponding to form &#x003b1; (REFCODE: PYRZIN) [<xref rid="B57-pharmaceuticals-18-00211" ref-type="bibr">57</xref>]. Its refinement resulted in R<sub>wp</sub> = 9.8% and <italic toggle="yes">S</italic> = 1.9. Lattice parameters are summarized in <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S6 (Supporting Information)</xref>.</p><p>The PXRD pattern of the DDEM shows the characteristics peaks of both ASA (form I) and PZA (form &#x003b1;) without peak shifts. Rietveld refinement (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S5, Supporting Information</xref>) confirms the presence of two crystalline phases within DDEM, with no evidence of detectable amounts of other crystalline phases. The absence of new peaks in the PXRD pattern indicates the absence of significant intermolecular interactions between the drug components, as expected in a eutectic mixture. The refinement accuracy of R<sub>wp</sub> = 7.8% and <italic toggle="yes">S</italic> = 1.6 suggests a good fit between the experimental and calculated diffraction patterns.</p><p><xref rid="pharmaceuticals-18-00211-f004" ref-type="fig">Figure 4</xref> shows the infrared (IR) spectra of ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, DDEM and PM. <xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S7 (Supporting Information)</xref> summarizes the vibrational bands, which are characteristics of form I for ASA<sub>LAG</sub> [<xref rid="B40-pharmaceuticals-18-00211" ref-type="bibr">40</xref>] and form &#x003b1; of PZA<sub>LAG</sub> [<xref rid="B58-pharmaceuticals-18-00211" ref-type="bibr">58</xref>].</p><p>The IR spectra of ASA<sub>LAG</sub> shows characteristic vibrations associated with the aromatic rings at 3040&#x02013;3100 cm<sup>&#x02212;1</sup>, while the -CH<sub>3</sub> stretching vibrations appear at 2770&#x02013;2850 cm<sup>&#x02212;1</sup>. The bands at 2770&#x02013;2850 cm<sup>&#x02212;1</sup> are due to the symmetrical and antisymmetrical stretching vibrations of the -CH<sub>3</sub>. Intense C=O bands are observed at 1754 and 1692 cm<sup>&#x02212;1</sup>. The <italic toggle="yes">v</italic>C=C aromatic vibration occurs at 1605 cm<sup>&#x02212;1</sup>, <italic toggle="yes">v</italic>C-O-H in-plane vibration at 1457 cm<sup>&#x02212;1</sup>, and <italic toggle="yes">v</italic>O-H plane in-plane vibration at 1419 and 1371 cm<sup>&#x02212;1</sup>. A strong &#x003b4;<sub>as,s</sub>C-H strain vibration appears at 1303 cm<sup>&#x02212;1</sup>, <italic toggle="yes">v</italic>C-O vibration at 1221 cm<sup>&#x02212;1</sup>, and <italic toggle="yes">v</italic>OC=C vibration at 1188 cm<sup>&#x02212;1</sup>. Out-of-plane C-H bending of the phenyl ring occurs at 917, 840, 803, and 754 cm<sup>&#x02212;1</sup>, while the out-of-plane C-C bending occurs at 704 cm<sup>&#x02212;1</sup>.</p><p>PZA<sub>LAG</sub> shows NH<sub>2</sub> stretching vibrations (symmetrical and antisymmetrical) at 3414 cm<sup>&#x02212;1</sup> and symmetrical vibrations a at 3364 (sh), 3211 (sh) and 3163 cm<sup>&#x02212;1</sup>. The <italic toggle="yes">v</italic>(CH) vibration appears at 3086 cm<sup>&#x02212;1</sup>, and the amide <italic toggle="yes">v</italic>(C=O) + &#x003b4;(NH<sub>2</sub>) vibration at 1714 cm<sup>&#x02212;1</sup>. Amide &#x003b4;(NH<sub>2</sub>) in-plane bending occurs at 1611 cm<sup>&#x02212;1</sup>, and pyrazine ring vibrations are observed at 1582, 1525, 1479, and 1438 cm<sup>&#x02212;1</sup>. The <italic toggle="yes">v</italic>(C-N) vibration appears at 1379 cm<sup>&#x02212;1</sup>, and other bands at lower wavenumbers correspond to pyrazine ring bending.</p><p>The IR spectra of the pure components and the eutectic mixture exhibited a high degree of similarity, with no significant shifts in peak positions. This observation suggests that the eutectic formation does not involve strong intermolecular interactions between the drug molecules. Instead, the components retain their individual molecular structures within the eutectic mixture.</p><p><xref rid="pharmaceuticals-18-00211-f005" ref-type="fig">Figure 5</xref> shows the Raman spectra of ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, DDEM, and PM (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S8 in Supporting Information</xref>, which lists the corresponding wavenumbers) [<xref rid="B36-pharmaceuticals-18-00211" ref-type="bibr">36</xref>,<xref rid="B59-pharmaceuticals-18-00211" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceuticals-18-00211" ref-type="bibr">60</xref>]. The Raman spectra of the DDEM closely resemble those of the individual components, with no significant shifts in peak positions. This observation further supports the formation of a simple eutectic mixture, where the components retain their individual molecular structures and weak intermolecular interactions. In contrast, the formation of cocrystals or salts would involve stronger intermolecular interactions and result in significant changes in the vibrational spectra [<xref rid="B2-pharmaceuticals-18-00211" ref-type="bibr">2</xref>].</p></sec><sec id="sec2dot3-pharmaceuticals-18-00211"><title>2.3. Computational Studies</title><p>For an eutectic mixture to form, the components must be miscible in the liquid state but immiscible in the solid state. In this system, the components must have compatible functional groups that can form weak intermolecular interactions, such as hydrogen bonding, van der Waals forces, or dipole&#x02013;dipole interaction [<xref rid="B61-pharmaceuticals-18-00211" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00211" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00211" ref-type="bibr">63</xref>]. These interactions can lower the melting point of the mixture and stabilize the eutectic phase.</p><p>To investigate the electronic structure and reactivity of ASA and PZA, density functional theory (DFT) calculations were performed. The geometries of ASA and PZA were optimized using the <italic toggle="yes">&#x003c9;</italic>B97X-D functional and the 6-311++G(d,p) basis set in the gas phase. Frontier molecular orbitals (HOMO and LUMO) were calculated to determine reactivity descriptors such as chemical hardness (<italic toggle="yes">&#x003b7;</italic>), softness (<italic toggle="yes">&#x003c3;</italic>), electronegativity (<italic toggle="yes">&#x003c7;</italic>), chemical potential (<italic toggle="yes">&#x003bc;</italic>), and global electrophilicity index (<italic toggle="yes">&#x003c9;</italic>). These descriptors provide insights into the molecular reactivity and possible molecular interactions [<xref rid="B61-pharmaceuticals-18-00211" ref-type="bibr">61</xref>].</p><p>The HOMO is associated with electron-donating ability, and its negative energy corresponds to the ionization energy (IE). The LUMO is related to electron-accepting ability, and its negative energy corresponds to the electron affinity (EA), according to Koopmans&#x02019; theorem [<xref rid="B64-pharmaceuticals-18-00211" ref-type="bibr">64</xref>]. <xref rid="pharmaceuticals-18-00211-f006" ref-type="fig">Figure 6</xref> shows the spatial distribution of the HOMO and LUMO of ASA and PZA.</p><p>HOMO energy of ASA is &#x02212;9.33 eV and its LUMO energy is 0.03 eV, resulting in a HOMO-LUMO gap (HLG) of 9.36 eV. HOMO energy of PZA is &#x02212;9.36 eV and its LUMO energy is &#x02212;0.42 eV, with an HLG of 8.94 eV. The larger HLG for ASA and PZA indicates their relative stability. The HLG explains the final charge transfer interactions within a molecule and is helpful in determining its electrical transport properties. A molecule with a large HLG exhibits low chemical reactivity and high kinetic stability, as it is energetically unfavorable to add an electron to the high-lying LUMO in order to remove electrons from the low-lying HOMO. Compounds with a larger HLG tend to be more stable compared to those with a smaller HLG [<xref rid="B65-pharmaceuticals-18-00211" ref-type="bibr">65</xref>]. <xref rid="pharmaceuticals-18-00211-t002" ref-type="table">Table 2</xref> summarizes the chemical reactivity indices calculated from the HOMO and LUMO energies for ASA and PZA (see <xref rid="sec3dot4-pharmaceuticals-18-00211" ref-type="sec">Section 3.4</xref>).</p><p>The <italic toggle="yes">&#x003b7;</italic> and <italic toggle="yes">&#x003c3;</italic> are key factors in assessing reactivity. The <italic toggle="yes">&#x003b7;</italic> values reflects resistance to electron density redistribution, while <italic toggle="yes">&#x003c3;</italic> is its inverse, with softer molecules being easier to polarize [<xref rid="B61-pharmaceuticals-18-00211" ref-type="bibr">61</xref>]. The <italic toggle="yes">&#x003bc;</italic> and <italic toggle="yes">&#x003c7;</italic> are also calculated from HOMO and LUMO energies, with <italic toggle="yes">&#x003bc;</italic> relates to electron escaping tendency, and <italic toggle="yes">&#x003c7;</italic> to electron-withdrawing ability. The global electrophilicity index (<italic toggle="yes">&#x003c9;</italic>), calculated from <italic toggle="yes">&#x003bc;</italic> and <italic toggle="yes">&#x003b7;</italic>, is associated with electron pair affinity and biological activity [<xref rid="B64-pharmaceuticals-18-00211" ref-type="bibr">64</xref>,<xref rid="B66-pharmaceuticals-18-00211" ref-type="bibr">66</xref>]. In summary, the <italic toggle="yes">&#x003c9;</italic> defines the tendency of electron acceptors to receive more electronic charges from the environment [<xref rid="B67-pharmaceuticals-18-00211" ref-type="bibr">67</xref>]. The &#x003c9; value of ASA and PZA were 2.31 and 2.67 eV, respectively. This indicates that PZA is more electrophilic than ASA, having a greater tendency to associate with a nucleophile.</p><p>Dipole moment, which reflects the charge separation within a molecule, significantly influences the molecule&#x02019;s polarity and aqueous solubility [<xref rid="B61-pharmaceuticals-18-00211" ref-type="bibr">61</xref>]. ASA and PZA have dipole moments of 3.28 D (Deybe) and 4.19 D, respectively (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S6, Supporting Information</xref>), and a tendency to interact with water molecules. These drugs have good aqueous solubility as demonstrated in this work. This dipole moment is the result of the non-uniform distribution of the positive and negative charges on the various atoms of ASA and PZA, due to the difference in electronegativity [<xref rid="B68-pharmaceuticals-18-00211" ref-type="bibr">68</xref>]. Thus, the dipole moment is related to the polarity of the molecules, influencing miscibility in other solvents and solubility in water [<xref rid="B61-pharmaceuticals-18-00211" ref-type="bibr">61</xref>].</p><p>Electrostatic potential maps (EPMs) were calculated for ASA and PZA using Multiwfn software [<xref rid="B69-pharmaceuticals-18-00211" ref-type="bibr">69</xref>]. Red, blue, and green represent negative, positive, and near zero electrostatic potential regions, respectively. The EPMs of ASA and PZA (<xref rid="pharmaceuticals-18-00211-f007" ref-type="fig">Figure 7</xref>) were obtained from the optimized geometries.</p><p>The EPM of ASA (<xref rid="pharmaceuticals-18-00211-f007" ref-type="fig">Figure 7</xref>a) shows higher electron density around oxygen atoms (O2: &#x02212;1.43 eV and O4: &#x02212;1.56 eV) and the lower density around hydrogen atoms (H1: 2.31 eV, H7: 0.97 eV). In PZA (<xref rid="pharmaceuticals-18-00211-f007" ref-type="fig">Figure 7</xref>b), the region around the oxygen atom O1 has higher electron density (&#x02212;1.73 eV), while carbon and hydrogen atoms have lower density regions (green and blue). In the EPMs shown in <xref rid="pharmaceuticals-18-00211-f007" ref-type="fig">Figure 7</xref>, we can highlight functional groups that are important for the therapeutic action of these drugs, and which may also participate in physical interactions to form the eutectic compound reported in this work.</p><p>The acetyl group of ASA is responsible for its therapeutic action. Its efficacy is associated with the inhibition of cyclooxygenase (COX) [<xref rid="B70-pharmaceuticals-18-00211" ref-type="bibr">70</xref>]. This enzyme participates in the synthesis of prostaglandins, substances that play a crucial role in inflammatory processes, pain, and fever (causing anti-inflammatory, analgesic, and antipyretic effects) [<xref rid="B35-pharmaceuticals-18-00211" ref-type="bibr">35</xref>,<xref rid="B70-pharmaceuticals-18-00211" ref-type="bibr">70</xref>]. The therapeutic action of PZA is related to the pyrazine functional group, which consists of a pyrazine ring. This ring contains nitrogen atoms in specific positions, which are essential for the substance&#x02019;s antimicrobial activity. The action of pyrazinamide in tuberculosis is linked to its ability to acidify the intracellular environment [<xref rid="B16-pharmaceuticals-18-00211" ref-type="bibr">16</xref>,<xref rid="B71-pharmaceuticals-18-00211" ref-type="bibr">71</xref>].</p><p>The computational studies provided valuable insights into the molecular interactions between ASA and PZA. The calculated dipole moments and electrostatic potential maps revealed the charge distribution on the molecular surfaces, highlighting potential sites for intermolecular interactions, such as hydrogen bonding and dipole&#x02013;dipole interactions. These interactions can influence the formation and stability of the eutectic mixture by facilitating the mixing of the components in the molten state and promoting specific molecular arrangements upon solidification. By understanding these interactions, researchers can gain a deeper understanding of the factors that contribute to eutectic formation and design strategies to optimize their properties for improved drug delivery and therapeutic efficacy.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00211"><title>2.4. Hygroscopicity Measurements</title><p><xref rid="pharmaceuticals-18-00211-f008" ref-type="fig">Figure 8</xref> shows the weight increases of ASA, PZA, DDEM, and PM after storage at 98% RH and 28 &#x000b0;C for 30 days (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Table S9 in Supporting Information</xref>). Callahan et al. [<xref rid="B72-pharmaceuticals-18-00211" ref-type="bibr">72</xref>] proposed a classification scheme for excipients based on moisture absorption. The European Pharmacopeia adapted a simple version, categorizing pharmaceutical excipients into four groups: non-hygroscopic; slightly hygroscopic; moderately hygroscopic, and very hygroscopic [<xref rid="B73-pharmaceuticals-18-00211" ref-type="bibr">73</xref>].</p><p>ASA and DDEM showed no weight gain after 30 days (non-hygroscopic). PZA and PM gained 0.6% (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) and 2.0% (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>), respectively, and are classified as slightly hygroscopic. Hygroscopicity can negatively impact the physical and chemical stability, solubility, and dissolution rate of drugs. The lower hygroscopicity of the DDEM compared to the physical mixture suggests improved stability and potential advantages in formulation development [<xref rid="B73-pharmaceuticals-18-00211" ref-type="bibr">73</xref>].</p></sec><sec id="sec2dot5-pharmaceuticals-18-00211"><title>2.5. Solubility and Dissolution Behavior</title><p>Solubility is a thermodynamic parameter that influences the bioavailability of pharmaceutical solids and is defined as the concentration of an active pharmaceutical ingredient at the equilibrium between the dissolved and non-dissolved compound [<xref rid="B74-pharmaceuticals-18-00211" ref-type="bibr">74</xref>]. ASA and PZA are orally administered drugs and are well absorbed in the gastrointestinal tract [<xref rid="B75-pharmaceuticals-18-00211" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-18-00211" ref-type="bibr">76</xref>]. Phosphate buffer (pH = 6.80 &#x000b1; 0.05) is commonly used in solubility tests to simulate the pH of the jejunum (pH 5.9&#x02013;6.8) [<xref rid="B20-pharmaceuticals-18-00211" ref-type="bibr">20</xref>,<xref rid="B35-pharmaceuticals-18-00211" ref-type="bibr">35</xref>,<xref rid="B38-pharmaceuticals-18-00211" ref-type="bibr">38</xref>,<xref rid="B77-pharmaceuticals-18-00211" ref-type="bibr">77</xref>]. It is used as a substitute for the physiological buffer (bicarbonate) to avoid instability in the pH value [<xref rid="B78-pharmaceuticals-18-00211" ref-type="bibr">78</xref>].</p><p>The aqueous solubility of ASA and PZA, both individually and within the DDEM and PM was determined (<xref rid="pharmaceuticals-18-00211-t003" ref-type="table">Table 3</xref>). The individual solubilities of ASA and PZA were 16.1 mg.mL<sup>&#x02212;1</sup> and 22.6 mg.mL<sup>&#x02212;1</sup>, respectively, which align with the value of 22 mg.mL<sup>&#x02212;1</sup> reported by Luo et al. [<xref rid="B74-pharmaceuticals-18-00211" ref-type="bibr">74</xref>] for PZA. Interestingly, simply mixing ASA and PZA (physical mixture) increased their aqueous solubility compared to the pure crystalline forms (<xref rid="pharmaceuticals-18-00211-t003" ref-type="table">Table 3</xref>).</p><p>The in vitro dissolution profiles of crystalline ASA and PZA, as well as those of the eutectic mixture and physical mixture, are presented in <xref rid="pharmaceuticals-18-00211-f009" ref-type="fig">Figure 9</xref>. ASA and PZA exhibited rapid release, with 85.1% and 97.7% dissolved within 10 min, respectively (<xref rid="pharmaceuticals-18-00211-t004" ref-type="table">Table 4</xref>). The ASA in the eutectic mixture showed a significant increase in % release (Q<sub>10min</sub>) in 10 min compared to the ASA<sub>FCB</sub> (free crystalline base) and the ASA in the physical mixture ASA-PZA (2:1)<sub>PM</sub>. The formation of DDEM is advantageous and facilitates the dissolution of ASA. Thus, this increase can be attributed to the small particle size of the drugs in the eutectic mixture obtained by the LAG method, improving their aqueous solubility and, consequently, the amount of drug released [<xref rid="B79-pharmaceuticals-18-00211" ref-type="bibr">79</xref>].</p><p>The similarity factor (<italic toggle="yes">f</italic><sub>2</sub>) was used to compare the dissolution profiles of ASA and PZA from the eutectic and physical mixtures and the pure compound (<xref rid="pharmaceuticals-18-00211-t004" ref-type="table">Table 4</xref>). As a reminder, <italic toggle="yes">f</italic><sub>2</sub> values below 50 indicate significant differences in release profiles, while values above 50 suggest similar profiles [<xref rid="B80-pharmaceuticals-18-00211" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceuticals-18-00211" ref-type="bibr">81</xref>]. The <italic toggle="yes">f</italic><sub>2</sub> values for the physical mixture (ASA: 71.36, PZA: 68.68) and the eutectic mixture (ASA: 60.04, PZA: 89.69) indicate similar dissolution profiles compared to pure ASA and PZA. The calculated <italic toggle="yes">f</italic><sub>2</sub> values indicate that the dissolution profiles exhibit high similarity, suggesting minimal differences in release behavior between the formulations. Additionally, the dissolution efficiency (DE) (<xref rid="pharmaceuticals-18-00211-t004" ref-type="table">Table 4</xref>) confirms that the eutectic and physical mixtures release ASA and PZA similarly in the conditions performed.</p><p>The aqueous solubility and dissolution profile of a compound are often linked to its melting point (T<italic toggle="yes"><sub>fus</sub></italic>) and enthalpy of fusion (&#x00394;H<italic toggle="yes"><sub>fus</sub></italic>). High T<italic toggle="yes"><sub>fus</sub></italic> and &#x00394;H<italic toggle="yes"><sub>fus</sub></italic> values typically indicate strong intermolecular interactions and low solubility. While the formation of a binary eutectic solid can increase the entropy and enthalpy of the mixture, leading to a more favorable free energy of solution (&#x00394;G) and potential improved solubility [<xref rid="B4-pharmaceuticals-18-00211" ref-type="bibr">4</xref>], this was not the driving factor in this case. Thermodynamic analysis (<xref rid="pharmaceuticals-18-00211-t001" ref-type="table">Table 1</xref>) revealed that the eutectic mixture has a lower melting point than the individual components, but higher enthalpy and entropy of fusion. This resulted in a less negative &#x00394;G, explaining the limited increase in solubility observed in the saturation solubility study (<xref rid="pharmaceuticals-18-00211-t003" ref-type="table">Table 3</xref>) [<xref rid="B4-pharmaceuticals-18-00211" ref-type="bibr">4</xref>]. The increase in the solubility of ASA from 16.1 mg.mL<sup>&#x02212;1</sup> in the crystalline form to 26.0 mg.mL<sup>&#x02212;1</sup> in the DDEM, and the increase in PZA solubility from 22.6 mg.mL<sup>&#x02212;1</sup> to 42.0 mg.mL<sup>&#x02212;1</sup>, can be attributed to several factors. The formation of the eutectic mixture likely disrupts the crystal lattice structure of both ASA and PZA, leading to a decrease in lattice energy. This reduction in lattice energy facilitates the dissolution process, as less energy is required to break the intermolecular forces holding the solid together. Additionally, the increased molecular mobility and reduced particle size in the DDEM can enhance the dissolution rate and overall solubility of both ASA and PZA. This enhanced solubility can have significant implications for the pharmaceutical industry, as it can improve drug bioavailability and therapeutic efficacy.</p></sec></sec><sec id="sec3-pharmaceuticals-18-00211"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00211"><title>3.1. Materials</title><p>PZA (purity (p) &#x02265; 98.0%), ASA (p &#x02265; 99.0%), ethanol (EtOH, p &#x02265; 99.0%), methanol (MeOH, p &#x02265; 99.0%), potassium phosphate monobasic (p &#x02265; 99.0%), and potassium phosphate dibasic trihydrate (p &#x02265; 98.0%) were obtained from Sigma-Aldrich (St. Louis, MO, USA).</p></sec><sec id="sec3dot2-pharmaceuticals-18-00211"><title>3.2. Methods</title><p>Binary mixtures of ASA and PZA, with molar ratios ranging from 5:1 to 1:5 (&#x003c7;<sub>ASA</sub> = 0.83, 0.80, 0.75, 0.67, 0.50, 0.33, 0.25, 0.20, and 0.17), were prepared. Each mixture (101 mg total mass) was subjected to liquid-assisted grinding (LAG) using 6 drops of ethanol for 20 min in a mortar and pestle. Residual solvent was removed from the resulting mixtures by drying them at 50.0 &#x000b1; 1.0 &#x000b0;C for 2 h, followed by storage to remove any residual solvent and stored in a desiccator.</p><p>For comparison, both pure ASA and PZA were milled, hereafter referred as ASA<sub>LAG</sub> and PZA<sub>LAG</sub>, respectively, and characterized to assess any potential polymorphic changes induced by the milling process. Additionally, a physical mixture of ASA and PZA in a 2:1 molar ratio (ASA-PZA (2:1)<sub>PM</sub>) was prepared by gently mixing in a mortar-pestle for 2 min. All experiments were performed in triplicate.</p></sec><sec id="sec3dot3-pharmaceuticals-18-00211"><title>3.3. Solid State Characterization</title><sec id="sec3dot3dot1-pharmaceuticals-18-00211"><title>3.3.1. Differential Scanning Calorimetry (DSC)</title><p>Differential scanning calorimetry (DSC) measurements were conducted using a DSC-60 calorimeter (Shimadzu Instruments, Columbia, MD, USA). Each sample, weighing approximately 2.00 mg, was transferred to an aluminum crucible. The experiments were performed under a nitrogen purge gas flow of 50 mL.min<sup>&#x02212;1</sup> using a closed crucible, with an empty crucible as reference. Samples were heated at a rate of 10 &#x000b0;C.min<sup>&#x02212;1</sup> over the temperature range of 25&#x02013;190 &#x000b0;C, which encompasses the melting point range of the components and potential eutectic formation. The DSC instrument was calibrated for temperature and enthalpy using indium (purity 99.99%; melting point = 156.6 &#x000b0;C; melting enthalpy = 28.45 J.g<sup>&#x02212;1</sup>) as a standard. All DSC analyses were carried out in triplicate.</p><list list-type="bullet"><list-item><p>Binary phase diagram and Tammann&#x02019;s triangle</p></list-item></list><p>Mixtures were prepared using the molar ratios of ASA defined above. The melting points and enthalpies of fusion of these mixtures were used to construct the binary phase diagram and Tammann&#x02019;s triangle, respectively.</p><p>The theoretical binary phase diagram was calculated using the Schr&#x000f6;der&#x02013;Van Laar Equation (1):<disp-formula id="FD1-pharmaceuticals-18-00211"><label>(1)</label><mml:math id="mm13" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi></mml:mrow><mml:mo>&#x02061;</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi>X</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>&#x02206;</mml:mo><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mfenced separators="|"><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x02212;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x02206;<italic toggle="yes">H</italic><sub>0</sub> is the enthalpy of fusion (J.mol<sup>&#x02212;1</sup>), <italic toggle="yes">T</italic><sub>0</sub> (K) is the melting temperature of the pure compounds, <italic toggle="yes">T</italic> (K) is the melting point of the mixture at mole fraction, <italic toggle="yes">X</italic>, and <italic toggle="yes">R</italic> is the gas constant (8.31447 J.K<sup>&#x02212;1</sup>.mol<sup>&#x02212;1</sup>) [<xref rid="B82-pharmaceuticals-18-00211" ref-type="bibr">82</xref>].</p><list list-type="bullet"><list-item><p>Thermochemistry</p></list-item></list><p>If a eutectic mixture is formed by simple mechanical mixing of two components without any solvent-mediated association, the molar enthalpy of fusion can be determined using the law of mixtures. The characterization of eutectic fusion is then achieved by calculating the mixing enthalpy <inline-formula><mml:math id="mm14" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula><italic toggle="yes">H</italic> [<xref rid="B50-pharmaceuticals-18-00211" ref-type="bibr">50</xref>]:<disp-formula id="FD2-pharmaceuticals-18-00211"><label>(2)</label><mml:math id="mm15" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msup><mml:mi>H</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm16" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the experimentally determined molar enthalpy of fusion and <inline-formula><mml:math id="mm17" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the corresponding calculated value using the following equation:<disp-formula id="FD3-pharmaceuticals-18-00211"><label>(3)</label><mml:math id="mm18" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="mm19" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm20" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> are the mole fractions of components 1 and 2, respectively, and <inline-formula><mml:math id="mm21" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm22" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> are their respective molar enthalpies of fusion.</p></sec><sec id="sec3dot3dot2-pharmaceuticals-18-00211"><title>3.3.2. Thermogravimetry and Differential Thermal Analysis (TG-DTA)</title><p>Thermogravimetric analysis (TGA) and differential thermal analysis (DTA) were performed simultaneously using a DTG-60 thermogravimetric analyzer (Shimadzu Instruments, Columbia, MD, USA). Approximately 5 mg of each sample was placed in an &#x003b1;-alumina crucible and heated from 25 &#x000b0;C to 600 &#x000b0;C at a heating rate of 10 &#x000b0;C.min<sup>&#x02212;1</sup> under a nitrogen atmosphere (50 mL.min<sup>&#x02212;1</sup>).</p></sec><sec id="sec3dot3dot3-pharmaceuticals-18-00211"><title>3.3.3. Powder X-Ray Diffraction (PXRD)</title><p>Powder X-ray diffraction (PXRD) patterns were collected on an Empyrean diffractometer (PANanalytical, Almelo, The Netherlands) using a CuK&#x003b1; radiation (<italic toggle="yes">&#x003bb;</italic> = 1.5418 &#x000c5;). The instrument was operated at 40 kV and 30 mA, with a step size 0.02&#x000b0; and scan range of 5&#x02013;45&#x000b0; (2<italic toggle="yes">&#x003b8;</italic>). The acquisition time was 2.0 s per step. PXRD data for recrystallized samples and starting materials were compared to the Cambridge Structural Database (CSD) using CCDC ConQuest software (version 2021.3.0) to identify potential crystalline phases and polymorphs.</p></sec><sec id="sec3dot3dot4-pharmaceuticals-18-00211"><title>3.3.4. Fourier Transform Infrared Spectroscopy (FT-IR)</title><p>Fourier transform infrared (FT-IR) spectroscopy was performed using a Vertex70v spectrometer (Bruker, Rosenheim, Germany). Spectra were collected in the 4000&#x02013;400 cm<sup>&#x02212;1</sup> range with a resolution of 4 cm<sup>&#x02212;1</sup> with 32 scans at room temperature. KBr pellets were used for samples preparation.</p></sec><sec id="sec3dot3dot5-pharmaceuticals-18-00211"><title>3.3.5. Raman Spectroscopy</title><p>Raman spectroscopy was performed in a T64000 spectrometer (Horiba Jobin-Yvon Kyoto, Japan) operating in single mode equipped with a liquid-nitrogen-cooled CCD detector. A 532 nm laser (solid state laser, 14 mW, LAS-532-100 HREV, Horiba Jobin-Yvon Kyoto, Japan) was used for excitation, and the slit was adjusted to achieve a resolution of 2 cm<sup>&#x02212;1</sup>. Spectra were acquired after 3 acquisitions with 30 s integration at each spectral range.</p></sec></sec><sec id="sec3dot4-pharmaceuticals-18-00211"><title>3.4. Computational Details</title><p>All computational calculations were performed using Gaussian 16 software with density functional theory (DFT). Geometry optimization and vibrational frequencies calculations for ASA and PZA were conducted using the <italic toggle="yes">&#x003c9;</italic>B97X-D functional and the 6-311++G(d) basis set [<xref rid="B83-pharmaceuticals-18-00211" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceuticals-18-00211" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceuticals-18-00211" ref-type="bibr">85</xref>]. Input files were prepared using Avogadro software with geometries obtained from the CSD [<xref rid="B86-pharmaceuticals-18-00211" ref-type="bibr">86</xref>]. ChemCraft software was used to analyze output files and create visualizations [<xref rid="B86-pharmaceuticals-18-00211" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-18-00211" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceuticals-18-00211" ref-type="bibr">88</xref>]. DFT calculations were performed to investigate the electronic structure, molecular properties, and potential intermolecular interactions between the drug molecules in the DDEM. <xref rid="pharmaceuticals-18-00211-t005" ref-type="table">Table 5</xref> presents the calculated reactivity descriptors and their corresponding equations [<xref rid="B64-pharmaceuticals-18-00211" ref-type="bibr">64</xref>,<xref rid="B66-pharmaceuticals-18-00211" ref-type="bibr">66</xref>].</p></sec><sec id="sec3dot5-pharmaceuticals-18-00211"><title>3.5. Hygroscopicity Measurements</title><p>To assess hygroscopicity, three replicates of ASA, PZA, the PM, and the DDEM were stored at 28.0 &#x000b1; 1.0 &#x000b0;C and 98% relative humidity (RH). A saturated ammonium phosphate solution was used to maintain the desired RH [<xref rid="B48-pharmaceuticals-18-00211" ref-type="bibr">48</xref>,<xref rid="B89-pharmaceuticals-18-00211" ref-type="bibr">89</xref>]. The weight change of each sample was monitored daily for the first 5 days and then on days 10, 15, and 30.</p></sec><sec id="sec3dot6-pharmaceuticals-18-00211"><title>3.6. Saturation Solubility Study</title><p>The equilibrium concentrations of ASA, PZA, and both components in the PM and the DDEM were determined in a 0.2M potassium phosphate buffer (pH 6.80) at 37.0 &#x000b1; 0.5 &#x000b0;C. A pH meter (HI 2221, Hanna Instruments, Bucharest, Romania) was calibrated using buffer solutions (pH 4.00, 7.00, and 10.00) to ensure accurate pH measurements.</p><p>Solubility was determined using the shake-flask method. Excess solid was added to the buffer solution and mixed for an extended period [<xref rid="B90-pharmaceuticals-18-00211" ref-type="bibr">90</xref>]. For each assay, 2898.25 mg of ASA and 1000.00 mg of PZA were added to 10.0 mL of buffer in a capped vial (area<sub>tube</sub> = 2.54 &#x000b1; 0.01 cm<sup>2</sup>). The vials were incubated at 37.0 &#x000b1; 0.5 &#x000b0;C for 24 h while shaking at 75 rpm in a shaker incubator. Subsequently, the solutions were filtered through a 0.45 &#x000b5;m cellulose membrane filter, and the filtrates were analyzed using UV&#x02013;vis spectrophotometry (UV-1900, Shimadzu, Kyoto, Japan) [<xref rid="B91-pharmaceuticals-18-00211" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-18-00211" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceuticals-18-00211" ref-type="bibr">93</xref>]. This study was conducted in triplicate, and the results were averaged.</p></sec><sec id="sec3dot7-pharmaceuticals-18-00211"><title>3.7. Dissolution Profile</title><p>The dissolution profiles of ASA, PZA, the PM, and the DDEM were evaluated using USP Apparatus II (paddle type). The sink conditions consisted of 450 mL of 0.2M potassium phosphate buffer (pH 6.80), preheated in a thermostatically controlled water bath at 37.0 &#x000b1; 0.5 &#x000b0;C. Approximately 449.10 mg of ASA and 150.00 mg of PZA were added to the dissolution medium, and the paddle speed was set to 75 rpm. Aliquots of 2.5 mL were withdrawn at predetermined time points (5, 10, 15, 30, 45, and 60 min) and replaced with fresh prewarmed buffer. The withdrawn samples were filtered through a 0.45 &#x000b5;m cellulose membrane filter, diluted, and analyzed using UV&#x02013;vis spectrophotometry at 226 nm for ASA and 269 nm for PZA.</p><p>Dissolution at 10 min (Q<sub>10min</sub>), dissolution efficiency (DE) at 10 min, and the similarity factor (<italic toggle="yes">f</italic><sub>2</sub>) were calculated using DDSolver [<xref rid="B94-pharmaceuticals-18-00211" ref-type="bibr">94</xref>]. Each experiment was conducted in triplicate.</p></sec><sec id="sec3dot8-pharmaceuticals-18-00211"><title>3.8. Quantification by UV&#x02013;VIS</title><p>Calibration curves were constructed using standard solutions of crystalline ASA and PZA (<xref rid="app1-pharmaceuticals-18-00211" ref-type="app">Figure S7, Supporting Information</xref>). ASA calibration standards were prepared in ethanol (EtOH) at concentrations ranging from 2.5 to 30.0 &#x000b5;g.mL<sup>&#x02212;1</sup> [<xref rid="B95-pharmaceuticals-18-00211" ref-type="bibr">95</xref>]. The regression coefficient (R<sup>2</sup>) was 0.9996, and the relative standard deviation (RSD) for all points was below 5%. PZA calibration standards were prepared in methanol (MeOH) at concentrations ranging from 4.0 to 20.0 &#x000b5;g.mL<sup>&#x02212;1</sup> [<xref rid="B96-pharmaceuticals-18-00211" ref-type="bibr">96</xref>]. The R<sup>2</sup> was 0.9992, and the RSD for all points was less than 3%. Both calibrations were performed in triplicate, and average values were used.</p><p>The absorbance of pure compounds and mixtures were measured at 226 nm and 269 nm. The absorbance of pure standards enabled the construction of calibration curves and the calculation of molar absorptivity coefficients for ASA and PZA at both wavelengths.</p><p>The concentrations of ASA and PZA in the PM and DDEM were determined by measuring the sample absorbance at specific wavelengths, using the following system Equation (12) [<xref rid="B97-pharmaceuticals-18-00211" ref-type="bibr">97</xref>]:<disp-formula id="FD4-pharmaceuticals-18-00211"><label>(12)</label><mml:math id="mm23" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced open="{" close="" separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>226</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>226</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>P</mml:mi><mml:mi>Z</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>226</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mn>269</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>269</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>P</mml:mi><mml:mi>Z</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:mfenced><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>269</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">A</italic><sub>226</sub> is the absorbance at 226 nm; <italic toggle="yes">A</italic><sub>269</sub> is the absorbance at 269 nm; and [<italic toggle="yes">ASA</italic>] and [<italic toggle="yes">PZA</italic>] are the molar concentrations of the drugs.</p></sec><sec id="sec3dot9-pharmaceuticals-18-00211"><title>3.9. Statistical Analysis</title><p>The data obtained from the experiments carried out in three replications were presented as mean &#x000b1; standard deviation, and relative standard deviation. The dissolution profiles were compared with the similarity factor (<italic toggle="yes">f</italic><sub>2</sub>) and calculated using the equation below [<xref rid="B94-pharmaceuticals-18-00211" ref-type="bibr">94</xref>]:<disp-formula id="FD5-pharmaceuticals-18-00211"><label>(13)</label><mml:math id="mm24" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mo>.</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mo>&#x02061;</mml:mo><mml:mrow><mml:mfenced open="{" close="}" separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:msup><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mfenced><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">n</italic> is the number of time points, <italic toggle="yes">R<sub>t</sub></italic> is the dissolved amount of the reference at time <italic toggle="yes">t</italic>, and <italic toggle="yes">T<sub>t</sub></italic> is the dissolved amount of the test at time <italic toggle="yes">t</italic>. If the <italic toggle="yes">f</italic><sub>2</sub> value was close to 100, the two curves were considered similar [<xref rid="B94-pharmaceuticals-18-00211" ref-type="bibr">94</xref>,<xref rid="B98-pharmaceuticals-18-00211" ref-type="bibr">98</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00211"><title>4. Conclusions</title><p>A novel ASA-PZA eutectic mixture (DDEM) was successfully prepared via liquid-assisted grinding and characterized by several techniques. DSC confirmed eutectic formation, revealing a single melting point at 114.2 &#x000b0;C (&#x00394;H<sub>fus</sub> = 119.31 kJ.mol<sup>&#x02212;1</sup>; &#x00394;S<sub>fus</sub> = 308.05 J/(mol.K)<sup>&#x02212;1</sup>), lower than that of the individual components. PXRD indicated no new phase formation, as no additional peaks were observed. Consistent with this, FT-IR and Raman spectroscopy showed highly similar spectra between the DDEM and the individual compounds, suggesting the absence of strong intermolecular interactions. Computational studies corroborated these findings, demonstrating that ASA and PZA are miscible in the liquid state (due to compatible functional groups enabling weak interactions) but immiscible in the solid state. The high HOMO-LUMO gaps for both ASA (9.36 eV) and PZA (8.94 eV) indicated good stability and low reactivity, with PZA exhibiting slightly higher electrophilicity. Dipole moment calculations (ASA: 3.28 D, PZA: 4.19 D) and EPMs identified potential hydrogen bonding and dipole&#x02013;dipole interaction sites, which are crucial for eutectic formation by promoting mixing in the molten state and influencing solidification. The EPMs also highlighted the involvement of key functional groups, including the acetyl group of ASA and the pyrazine ring, in both therapeutic activity and potential eutectic formation. Dissolution studies demonstrated enhanced ASA release from the DDEM (95.9%) compared to its ASA<sub>FCB</sub> form (85.1%) and the physical mixture (81.5%). This enhanced release is significant for potentially improving the combined therapeutic efficacy of the drugs, particularly given previous reports of ASA potentiating PZA&#x02019;s anti-tuberculosis activity. Future work will explore the thermodynamics and synergistic interactions of this eutectic, potentially through molecular dynamics simulations, to further elucidate the intermolecular interactions governing its formation and to inform the development of advanced drug delivery systems.</p></sec></body><back><ack><title>Acknowledgments</title><p>The researchers are grateful to the Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior&#x02014;Brasil (CAPES)&#x02014;Finance Code 001, the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa e Desenvolvimento Cient&#x000ed;fico do Estado do Maranh&#x000e3;o (FAPEMA). The authors acknowledge the computational resources of the Digital Research Alliance of Canada | l&#x02019;Alliance de recherche num&#x000e9;rique du Canada through the collaboration of Stanislav R. Stoyanov, Department of Chemical and Materials Engineering, University of Alberta.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00211"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020211/s1">https://www.mdpi.com/article/10.3390/ph18020211/s1</uri>, Figure S1: Molecular structure of (a) pyrazinamide (PZA, MW:123.11 g.mol<sup>&#x02212;1</sup>) and (b) acetylsalicylic acid (ASA, MW: 180.16 g.mol<sup>&#x02212;1</sup>); Figure S2: DSC curves of ground acetylsalicylic acid (ASA<sub>LAG</sub>), eutectic mixture ASA-PZA (2:1), physical mixture ASA-PZA (2:1)<sub>PM</sub> and ground pyrazinamide (PZA<sub>LAG</sub>) under nitrogen at a 50 mL.min<sup>&#x02212;1</sup> rate in an aluminum crucible. Each sample was heated at a rate of 10 &#x000b0;C.min<sup>&#x02212;1</sup>; Figure S3: TG/DTG-DTA analysis of (a) ground acetylsalicylic acid (ASA<sub>LAG</sub>), (b) eutectic mixture ASA-PZA (2:1), (c) physical mixture ASA-PZA (2:1)<sub>PM</sub> and (d) ground acetylsalicylic acid (PZA<sub>LAG</sub>); Figure S4: Rietveld refinement for (a) acid acetylsalicylic (ASA), (b) ground acid acetylsalicylic (ASA<sub>LAG</sub>), (c) pyrazinamide (PZA), and (d) ground pyrazinamide (PZA<sub>LAG</sub>); Figure S5: Rietveld refinement for eutectic mixture ASA-PZA (2:1); Figure S6: Optimized geometries for ASA (a) and PZA (b) in vacuum, obtained from calculations employing the DFT functional <italic toggle="yes">&#x003c9;</italic>B97X-D and 6-311G++(d,p) basis set; Figure S7: (a) Calibration curve obtained for the determination of ASA in ethanol; (b) average spectra of the calibration curve data points of ASA; (c) Calibration curve obtained for the determination of PZA in methanol; (d) average spectra of the calibration curve data points of PZA; Table S1: Thermal events observed in the DSC curves for ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, ASA-PZA mixtures and physical mixture ASA-PZA (2:1)<sub>PM</sub>; Table S2. Temperatures and enthalpies of fusion of the molar fractions investigated were used to construct the binary phase diagram and Tammann&#x02019; triangle to determine the stoichiometry of the ASA-PZA eutectic system; Table S3: Calculations of the theoretical melting temperatures for each molar fraction <italic toggle="yes">x</italic> for the binary mixtures of ASA and PZA investigated in this work; Table S4: Thermal events observed in the TG/DTG curves for the starting compounds (ASA<sub>LAG</sub> and PZA<sub>LAG</sub>), the eutectic mixture ASA-PZA (2:1) with their respective physical mixture ASA-PZA (2:1)<sub>PM</sub>; Table S5: Thermal events observed in the DTA curves for the starting compounds (ASA<sub>LAG</sub> and PZA<sub>LAG</sub>), the eutectic mixture ASA-PZA (2:1) and the physical mixture ASA-PZA (2:1)<sub>PM</sub>; Table S6: Crystal data and the lattice paraments of Rietveld refinement for ASA, ASA<sub>LAG</sub>, PZA and PZA<sub>LAG</sub>; Table S7: Vibrational frequencies observed in the FT-IR spectra of ASA<sub>LAG</sub> and PZA<sub>LAG</sub>; Table S8: Identification of the main frequencies in the Raman spectrum of ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, the physical mixture ASA-PZA (2:1)<sub>PM</sub>, and the eutectic mixture ASA-PZA (2:1) for the spectral region between 75 and 3600 cm<sup>&#x02212;1</sup>; Table S9: Weight data obtained from the hygroscopicity study of ASA, PZA, the physical mixture ASA-PZA (2:1)<sub>PM</sub>, and DDEM ASA-PZA (2:1) after storage at 98% RH and 28 &#x000b0;C for 30 days.</p><supplementary-material id="pharmaceuticals-18-00211-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00211-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>L.H.S.Q.: data curation, formal analysis, investigation, methodology, validation, roles/writing&#x02014;original draft. M.R.L.: theoretical calculations, methodology, writing&#x02014;review and editing. C.C.d.S.: formal analysis, methodology, writing&#x02014;review and editing. M.C.S.: investigation, methodology, validation, supervision, writing&#x02014;review and editing. P.R.S.R.: conceptualization, data curation, funding acquisition, investigation, methodology, validation, project administration, supervision, writing&#x02014;review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">DDEM</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug&#x02013;drug eutectic mixture</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASA</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetylsalicylic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PZA</td><td align="left" valign="middle" rowspan="1" colspan="1">Pyrazinamide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EM</td><td align="left" valign="middle" rowspan="1" colspan="1">Eutectic mixture</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LAG</td><td align="left" valign="middle" rowspan="1" colspan="1">Liquid-assisted grinding</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TB</td><td align="left" valign="middle" rowspan="1" colspan="1">Tuberculosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Biopharmaceutical classification system</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Differential Scanning Calorimetry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TG-DTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Thermogravimetry and differential thermal analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PXRD</td><td align="left" valign="middle" rowspan="1" colspan="1">Powder X-ray diffraction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FT-IR</td><td align="left" valign="middle" rowspan="1" colspan="1">Fourier transform infrared spectroscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POA</td><td align="left" valign="middle" rowspan="1" colspan="1">Pyrazinoic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FT-IR</td><td align="left" valign="middle" rowspan="1" colspan="1">Fourier transform infrared spectroscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DFT</td><td align="left" valign="middle" rowspan="1" colspan="1">Density functional theory</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00211"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuri Ger&#x000f4;nimo Kobata</surname><given-names>P.</given-names></name>
<name><surname>Ticona Chambi</surname><given-names>J.</given-names></name>
<name><surname>Maria do Espirito Santo</surname><given-names>A.</given-names></name>
<name><surname>Lucia Cuffini</surname><given-names>S.</given-names></name>
</person-group><article-title>Eutectic mixtures containing the active pharmaceutical ingredient ezetimibe: Phase diagrams, solid state characterization and dissolution profiles</article-title><source>J. Cryst. Growth</source><year>2024</year><volume>642</volume><fpage>127775</fpage><pub-id pub-id-type="doi">10.1016/j.jcrysgro.2024.127775</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-18-00211"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bazzo</surname><given-names>G.C.</given-names></name>
<name><surname>Pezzini</surname><given-names>B.R.</given-names></name>
<name><surname>Stulzer</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>588</volume><fpage>119741</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119741</pub-id><pub-id pub-id-type="pmid">32783978</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00211"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh Raman</surname><given-names>A.P.</given-names></name>
<name><surname>Jain</surname><given-names>P.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Kumari</surname><given-names>K.</given-names></name>
<name><surname>Bahadur</surname><given-names>I.</given-names></name>
<name><surname>Mohammad</surname><given-names>F.</given-names></name>
<name><surname>Kaushik</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Eutectic Mixtures to Enhance the Solubility of Active Pharmaceutical Ingredients: Density Functional Theory and Infrared Spectroscopy Approaches</article-title><source>ChemistrySelect</source><year>2023</year><volume>8</volume><fpage>e202300824</fpage><pub-id pub-id-type="doi">10.1002/slct.202300824</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-18-00211"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solares-Briones</surname><given-names>M.</given-names></name>
<name><surname>Coyote-Dotor</surname><given-names>G.</given-names></name>
<name><surname>P&#x000e1;ez-Franco</surname><given-names>J.C.</given-names></name>
<name><surname>Zerme&#x000f1;o-Ortega</surname><given-names>M.R.</given-names></name>
<name><surname>de la O Contreras</surname><given-names>C.M.</given-names></name>
<name><surname>Canseco-Gonz&#x000e1;lez</surname><given-names>D.</given-names></name>
<name><surname>Avila-Sorrosa</surname><given-names>A.</given-names></name>
<name><surname>Morales-Morales</surname><given-names>D.</given-names></name>
<name><surname>Germ&#x000e1;n-Acacio</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Mechanochemistry: A Green Approach in the Preparation of Pharmaceutical Cocrystals</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>790</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13060790</pub-id><pub-id pub-id-type="pmid">34070646</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00211"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Queiroz</surname><given-names>L.H.S.</given-names></name>
<name><surname>Barros</surname><given-names>R.S.</given-names></name>
<name><surname>de Sousa</surname><given-names>F.F.</given-names></name>
<name><surname>Lage</surname><given-names>M.R.</given-names></name>
<name><surname>Sarragu&#x000e7;a</surname><given-names>M.C.</given-names></name>
<name><surname>Ribeiro</surname><given-names>P.R.S.</given-names></name>
</person-group><article-title>Preparation and Characterization of a Rifampicin Coamorphous Material with Tromethamine Coformer: An Experimental&#x02013;Theoretical Study</article-title><source>Mol. Pharm.</source><year>2024</year><volume>21</volume><fpage>1272</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00947</pub-id><pub-id pub-id-type="pmid">38361428</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00211"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adalder</surname><given-names>T.K.</given-names></name>
<name><surname>Sankolli</surname><given-names>R.</given-names></name>
<name><surname>Dastidar</surname><given-names>P.</given-names></name>
</person-group><article-title>Homo- or Heterosynthon? A Crystallographic Study on a Series of New Cocrystals Derived from Pyrazinecarboxamide and Various Carboxylic Acids Equipped with Additional Hydrogen Bonding Sites</article-title><source>Cryst. Growth. Des.</source><year>2012</year><volume>12</volume><fpage>2533</fpage><lpage>2542</lpage><pub-id pub-id-type="doi">10.1021/cg300140w</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-18-00211"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bodart</surname><given-names>L.</given-names></name>
<name><surname>Derlet</surname><given-names>A.</given-names></name>
<name><surname>Buol</surname><given-names>X.</given-names></name>
<name><surname>Leyssens</surname><given-names>T.</given-names></name>
<name><surname>Tumanov</surname><given-names>N.</given-names></name>
<name><surname>Wouters</surname><given-names>J.</given-names></name>
</person-group><article-title>Combining two antitubercular drugs, clofazimine and 4-aminosalicylic acid, in order to improve clofazimine aqueous solubility and 4-aminosalicylic acid thermal stability</article-title><source>J. Pharm. Sci.</source><year>2020</year><volume>109</volume><fpage>3645</fpage><lpage>3652</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2020.09.024</pub-id><pub-id pub-id-type="pmid">32976899</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00211"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>J.P.A.</given-names></name>
<name><surname>Bansal</surname><given-names>A.K.</given-names></name>
<name><surname>Jain</surname><given-names>S.</given-names></name>
</person-group><article-title>Molecular Understanding and Implication of Structural Integrity in the Deformation Behavior of Binary Drug&#x02013;Drug Eutectic Systems</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>1917</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00077</pub-id><pub-id pub-id-type="pmid">29620908</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00211"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>B.-F.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Hao</surname><given-names>C.</given-names></name>
</person-group><article-title>Drug-drug eutectic mixtures of celecoxib with tapentadol and milnacipran which could improve analgesic and antidepressant efficacy</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>67</volume><fpage>102995</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102995</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-18-00211"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michalchuk</surname><given-names>A.A.L.</given-names></name>
</person-group><article-title>On the physical processes of mechanochemically induced transformations in molecular solids</article-title><source>Chem. Commun.</source><year>2024</year><volume>60</volume><fpage>14750</fpage><lpage>14761</lpage><pub-id pub-id-type="doi">10.1039/D4CC04062G</pub-id><pub-id pub-id-type="pmid">39611238</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00211"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andre</surname><given-names>V.</given-names></name>
<name><surname>Duarte</surname><given-names>M.T.</given-names></name>
<name><surname>Gomes</surname><given-names>C.S.B.</given-names></name>
<name><surname>Sarraguca</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Mechanochemistry in Portugal-A Step towards Sustainable Chemical Synthesis</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>241</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27010241</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-18-00211"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ying</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>W.</given-names></name>
</person-group><article-title>Liquid-Assisted Grinding Mechanochemistry in the Synthesis of Pharmaceuticals</article-title><source>Adv. Synth. Catal.</source><year>2021</year><volume>363</volume><fpage>1246</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1002/adsc.202001245</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-18-00211"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dartois</surname><given-names>V.A.</given-names></name>
<name><surname>Rubin</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Anti-tuberculosis treatment strategies and drug development: Challenges and priorities</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>685</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00731-y</pub-id><pub-id pub-id-type="pmid">35478222</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00211"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourguignon</surname><given-names>T.</given-names></name>
<name><surname>Godinez-Leon</surname><given-names>J.A.</given-names></name>
<name><surname>Gref</surname><given-names>R.</given-names></name>
</person-group><article-title>Nanosized Drug Delivery Systems to Fight Tuberculosis</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>393</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020393</pub-id><pub-id pub-id-type="pmid">36839715</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00211"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>A.E.</given-names></name>
<name><surname>Elasala</surname><given-names>G.S.</given-names></name>
<name><surname>Mohamed</surname><given-names>E.A.</given-names></name>
<name><surname>Kolkaila</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Spectral, thermal studies and biological activity of pyrazinamide complexes</article-title><source>Heliyon</source><year>2019</year><volume>5</volume><fpage>e02912</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2019.e02912</pub-id><pub-id pub-id-type="pmid">31844764</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00211"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Mitchison</surname><given-names>D.</given-names></name>
</person-group><article-title>Mechanisms of Pyrazinamide Action and Resistance</article-title><source>Microbiol. Spectr.</source><year>2014</year><volume>2</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.MGM2-0023-2013</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-18-00211"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitfield</surname><given-names>M.G.</given-names></name>
<name><surname>Soeters</surname><given-names>H.M.</given-names></name>
<name><surname>Warren</surname><given-names>R.M.</given-names></name>
<name><surname>York</surname><given-names>T.</given-names></name>
<name><surname>Sampson</surname><given-names>S.L.</given-names></name>
<name><surname>Streicher</surname><given-names>E.M.</given-names></name>
<name><surname>van Helden</surname><given-names>P.D.</given-names></name>
<name><surname>van Rie</surname><given-names>A.</given-names></name>
</person-group><article-title>A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0133869</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0133869</pub-id><pub-id pub-id-type="pmid">26218737</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00211"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Fang</surname><given-names>J.</given-names></name>
<name><surname>Bo</surname><given-names>Y.</given-names></name>
<name><surname>Xue</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>Z.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
</person-group><article-title>Terahertz and Raman Spectroscopic Investigation of Anti-tuberculosis Drug-Drug Cocrystallization Involving 4-aminosalicylic Acid and Pyrazinamide</article-title><source>J. Mol. Struct.</source><year>2021</year><volume>1227</volume><fpage>129547</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.129547</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-18-00211"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Mitchison</surname><given-names>D.</given-names></name>
</person-group><article-title>The curious characteristics of pyrazinamide: A review</article-title><source>Int. J. Tuberc. Lung Dis.</source><year>2003</year><volume>7</volume><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12701830</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00211"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Becker</surname><given-names>C.</given-names></name>
<name><surname>Dressman</surname><given-names>J.</given-names></name>
<name><surname>Amidon</surname><given-names>G.</given-names></name>
<name><surname>Junginger</surname><given-names>H.</given-names></name>
<name><surname>Kopp</surname><given-names>S.</given-names></name>
<name><surname>Midha</surname><given-names>K.</given-names></name>
<name><surname>Shah</surname><given-names>V.</given-names></name>
<name><surname>Stavchansky</surname><given-names>S.</given-names></name>
<name><surname>Barends</surname><given-names>D.</given-names></name>
</person-group><article-title>Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide</article-title><source>J. Pharm. Sci.</source><year>2008</year><volume>97</volume><fpage>3709</fpage><lpage>3720</lpage><pub-id pub-id-type="doi">10.1002/jps.21250</pub-id><pub-id pub-id-type="pmid">18271031</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00211"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amidon</surname><given-names>G.L.</given-names></name>
<name><surname>Lennern&#x000e4;s</surname><given-names>H.</given-names></name>
<name><surname>Shah</surname><given-names>V.P.</given-names></name>
<name><surname>Crison</surname><given-names>J.R.</given-names></name>
</person-group><article-title>A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability</article-title><source>Pharm. Res.</source><year>1995</year><volume>12</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1023/A:1016212804288</pub-id><pub-id pub-id-type="pmid">7617530</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00211"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherukuvada</surname><given-names>S.</given-names></name>
<name><surname>Thakuria</surname><given-names>R.</given-names></name>
<name><surname>Nangia</surname><given-names>A.</given-names></name>
</person-group><article-title>Pyrazinamide polymorphs: Relative stability and vibrational spectroscopy</article-title><source>Cryst. Growth. Des.</source><year>2010</year><volume>10</volume><fpage>3931</fpage><lpage>3941</lpage><pub-id pub-id-type="doi">10.1021/cg1004424</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-18-00211"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Liang</surname><given-names>Z.</given-names></name>
<name><surname>Ji</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Lan</surname><given-names>P.</given-names></name>
</person-group><article-title>The thermal behavior of pyrazinamide in 12 solvents from 288.15 to 328.15 k</article-title><source>J. Mol. Liq.</source><year>2021</year><volume>329</volume><fpage>115572</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2021.115572</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-18-00211"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McMahon</surname><given-names>J.A.</given-names></name>
<name><surname>Bis</surname><given-names>J.A.</given-names></name>
<name><surname>Vishweshwar</surname><given-names>P.</given-names></name>
<name><surname>Shattock</surname><given-names>T.R.</given-names></name>
<name><surname>McLaughlin</surname><given-names>O.L.</given-names></name>
<name><surname>Zaworotko</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Crystal engineering of the composition of pharmaceutical phases. 3. Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals</article-title><source>Z. F&#x000fc;r Krist.-Cryst. Mater.</source><year>2005</year><volume>220</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1524/zkri.220.4.340.61624</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-18-00211"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thorat</surname><given-names>S.H.</given-names></name>
<name><surname>Sahu</surname><given-names>S.K.</given-names></name>
<name><surname>Gonnade</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Crystal structures of the pyrazinamide&#x02013;p-aminobenzoic acid (1/1) cocrystal and the transamidation reaction product 4-(pyrazine-2-carboxamido) benzoic acid in the molten state</article-title><source>Acta Crystallogr. Sect. C Struct. Chem.</source><year>2015</year><volume>71</volume><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1107/S2053229615019828</pub-id><pub-id pub-id-type="pmid">26524176</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00211"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Otaibi</surname><given-names>J.S.</given-names></name>
<name><surname>Mary</surname><given-names>Y.S.</given-names></name>
<name><surname>Mary</surname><given-names>Y.S.</given-names></name>
<name><surname>Panicker</surname><given-names>C.Y.</given-names></name>
<name><surname>Thomas</surname><given-names>R.</given-names></name>
</person-group><article-title>Cocrystals of pyrazinamide with p-toluenesulfonic and ferulic acids: DFT investigations and molecular docking studies</article-title><source>J. Mol. Struct.</source><year>2019</year><volume>1175</volume><fpage>916</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2018.08.055</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-18-00211"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulla</surname><given-names>H.</given-names></name>
<name><surname>Greiser</surname><given-names>S.</given-names></name>
<name><surname>Benemann</surname><given-names>S.</given-names></name>
<name><surname>Rademann</surname><given-names>K.</given-names></name>
<name><surname>Emmerling</surname><given-names>F.</given-names></name>
</person-group><article-title>In situ investigation of a self-accelerated cocrystal formation by grinding pyrazinamide with oxalic acid</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>917</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21070917</pub-id><pub-id pub-id-type="pmid">27428942</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00211"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajbongshi</surname><given-names>T.</given-names></name>
<name><surname>Sarmah</surname><given-names>K.K.</given-names></name>
<name><surname>Sarkar</surname><given-names>A.</given-names></name>
<name><surname>Ganduri</surname><given-names>R.</given-names></name>
<name><surname>Cherukuvada</surname><given-names>S.</given-names></name>
<name><surname>Thakur</surname><given-names>T.S.</given-names></name>
<name><surname>Thakuria</surname><given-names>R.</given-names></name>
</person-group><article-title>Preparation of Pyrazinamide Eutectics versus Cocrystals Based on Supramolecular Synthon Variations</article-title><source>Cryst. Growth. Des.</source><year>2018</year><volume>18</volume><fpage>6640</fpage><lpage>6651</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.8b00878</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-18-00211"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bommaka</surname><given-names>M.K.</given-names></name>
<name><surname>Mannava</surname><given-names>M.C.</given-names></name>
<name><surname>Suresh</surname><given-names>K.</given-names></name>
<name><surname>Gunnam</surname><given-names>A.</given-names></name>
<name><surname>Nangia</surname><given-names>A.</given-names></name>
</person-group><article-title>Entacapone: Improving aqueous solubility, diffusion permeability, and cocrystal stability with theophylline</article-title><source>Cryst. Growth. Des.</source><year>2018</year><volume>18</volume><fpage>6061</fpage><lpage>6069</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.8b00921</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-18-00211"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c9;vora</surname><given-names>A.O.</given-names></name>
<name><surname>Castro</surname><given-names>R.A.</given-names></name>
<name><surname>Maria</surname><given-names>T.M.</given-names></name>
<name><surname>Rosado</surname><given-names>M.T.</given-names></name>
<name><surname>Ramos Silva</surname><given-names>M.</given-names></name>
<name><surname>Matos Beja</surname><given-names>A.</given-names></name>
<name><surname>Canotilho</surname><given-names>J.</given-names></name>
<name><surname>Eus&#x000e9;bio</surname><given-names>M.E.S.</given-names></name>
</person-group><article-title>Pyrazinamide-diflunisal: A new dual-drug co-crystal</article-title><source>Cryst. Growth. Des.</source><year>2011</year><volume>11</volume><fpage>4780</fpage><lpage>4788</lpage><pub-id pub-id-type="doi">10.1021/cg200288b</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-18-00211"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakuria</surname><given-names>R.</given-names></name>
<name><surname>Cherukuvada</surname><given-names>S.</given-names></name>
<name><surname>Nangia</surname><given-names>A.</given-names></name>
</person-group><article-title>Crystal structures of pyrogallol, its hydrate, and stable multiple Z&#x02032; cocrystals with N-heterocycles containing metastable conformers of pyrogallol</article-title><source>Cryst. Growth. Des.</source><year>2012</year><volume>12</volume><fpage>3944</fpage><lpage>3953</lpage><pub-id pub-id-type="doi">10.1021/cg3003367</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-18-00211"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eddleston</surname><given-names>M.D.</given-names></name>
<name><surname>Arhangelskis</surname><given-names>M.</given-names></name>
<name><surname>Fabian</surname><given-names>L.</given-names></name>
<name><surname>Tizzard</surname><given-names>G.J.</given-names></name>
<name><surname>Coles</surname><given-names>S.J.</given-names></name>
<name><surname>Jones</surname><given-names>W.</given-names></name>
</person-group><article-title>Investigation of an amide-pseudo amide hydrogen bonding motif within a series of theophylline: Amide cocrystals</article-title><source>Cryst. Growth. Des.</source><year>2016</year><volume>16</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.5b00905</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-18-00211"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Xue</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>Z.</given-names></name>
</person-group><article-title>Vibrational spectroscopic investigation into novel ternary eutectic formed between pyrazinamide, fumaric acid, and isoniazid</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>17266</fpage><lpage>17274</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c01486</pub-id><pub-id pub-id-type="pmid">32715212</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00211"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000f3;rniak</surname><given-names>A.</given-names></name>
<name><surname>Wojakowska</surname><given-names>A.</given-names></name>
<name><surname>Karolewicz</surname><given-names>B.</given-names></name>
<name><surname>Pluta</surname><given-names>J.</given-names></name>
</person-group><article-title>Phase diagram and dissolution studies of the fenofibrate&#x02013;acetylsalicylic acid system</article-title><source>J. Therm. Anal. Calorim.</source><year>2011</year><volume>104</volume><fpage>1195</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1007/s10973-010-1148-3</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-18-00211"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dressman</surname><given-names>J.B.</given-names></name>
<name><surname>Nair</surname><given-names>A.</given-names></name>
<name><surname>Abrahamsson</surname><given-names>B.</given-names></name>
<name><surname>Barends</surname><given-names>D.M.</given-names></name>
<name><surname>Groot</surname><given-names>D.</given-names></name>
<name><surname>Kopp</surname><given-names>S.</given-names></name>
<name><surname>Langguth</surname><given-names>P.</given-names></name>
<name><surname>Polli</surname><given-names>J.E.</given-names></name>
<name><surname>Shah</surname><given-names>V.P.</given-names></name>
<name><surname>Zimmer</surname><given-names>M.</given-names></name>
</person-group><article-title>Biowaiver monograph for immediate-release solid oral dosage forms: Acetylsalicylic acid</article-title><source>J. Pharm. Sci.</source><year>2012</year><volume>101</volume><fpage>2653</fpage><lpage>2667</lpage><pub-id pub-id-type="doi">10.1002/jps.23212</pub-id><pub-id pub-id-type="pmid">22674043</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00211"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crowell</surname><given-names>E.L.</given-names></name>
<name><surname>Dreger</surname><given-names>Z.A.</given-names></name>
<name><surname>Gupta</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>High-pressure polymorphism of acetylsalicylic acid (aspirin): Raman spectroscopy</article-title><source>J. Mol. Struct.</source><year>2015</year><volume>1082</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2014.10.079</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-18-00211"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kouskov&#x000e1;</surname><given-names>L.</given-names></name>
<name><surname>Leitner</surname><given-names>J.</given-names></name>
</person-group><article-title>DSC study of the system o-acetylsalicylic acid&#x02013;caffeine and thermodynamic modelling of the system o-acetylsalicylic acid&#x02013;caffeine&#x02013;paracetamol</article-title><source>Thermochim. Acta</source><year>2019</year><volume>674</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.tca.2019.02.007</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-18-00211"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osmanovi&#x00107; Omerdi&#x00107;</surname><given-names>E.</given-names></name>
<name><surname>Alagi&#x00107;-D&#x0017e;ambi&#x00107;</surname><given-names>L.</given-names></name>
<name><surname>Krsti&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Pa&#x00161;i&#x00107;-Kulenovi&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Odovi&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Vasiljevi&#x00107;</surname><given-names>D.</given-names></name>
</person-group><article-title>In vitro dissolution study of acetylsalicylic acid and clopidogrel bisulfate solid dispersions: Validation of the RP-HPLC method for simultaneous analysis</article-title><source>Appl. Sci.</source><year>2020</year><volume>10</volume><elocation-id>4792</elocation-id><pub-id pub-id-type="doi">10.3390/app10144792</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-18-00211"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Policianova</surname><given-names>O.</given-names></name>
<name><surname>Brus</surname><given-names>J.</given-names></name>
<name><surname>Hruby</surname><given-names>M.</given-names></name>
<name><surname>Urbanova</surname><given-names>M.</given-names></name>
</person-group><article-title>In vitro dissolution study of acetylsalicylic acid solid dispersions. Tunable drug release allowed by the choice of polymer matrix</article-title><source>Pharm. Dev. Technol.</source><year>2015</year><volume>20</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3109/10837450.2014.943407</pub-id><pub-id pub-id-type="pmid">25047056</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00211"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tita</surname><given-names>D.</given-names></name>
<name><surname>Jurca</surname><given-names>T.</given-names></name>
<name><surname>Fulias</surname><given-names>A.</given-names></name>
<name><surname>Marian</surname><given-names>E.</given-names></name>
<name><surname>Tita</surname><given-names>B.</given-names></name>
</person-group><article-title>Compatibility study of the acetylsalicylic acid with different solid dosage forms excipients</article-title><source>J. Therm. Anal. Calorim.</source><year>2013</year><volume>112</volume><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/s10973-013-2937-2</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-18-00211"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Huang</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>D.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>K.</given-names></name>
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Jiang</surname><given-names>T.</given-names></name>
</person-group><article-title>Preparation and functionalization of acetylsalicylic acid loaded chitosan/gelatin membranes from ethanol-based suspensions via electrophoretic deposition</article-title><source>J. Mater. Chem. B</source><year>2018</year><volume>6</volume><fpage>2304</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1039/C7TB03033A</pub-id><pub-id pub-id-type="pmid">32254569</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00211"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>S.T.</given-names></name>
<name><surname>Denkin</surname><given-names>S.M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis</article-title><source>J. Antimicrob. Chemother.</source><year>2007</year><volume>59</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl486</pub-id><pub-id pub-id-type="pmid">17185297</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00211"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alea</surname><given-names>G.V.</given-names></name>
<name><surname>Lagua</surname><given-names>F.M.G.</given-names></name>
<name><surname>Ajero</surname><given-names>M.D.M.</given-names></name>
</person-group><article-title>Synthesis and characterization of pyrazinamide analogs of acetylsalicylic acid and salicylic acid</article-title><source>Philipp. J. Sci.</source><year>2017</year><volume>146</volume><fpage>457</fpage><lpage>468</lpage></element-citation></ref><ref id="B44-pharmaceuticals-18-00211"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Villagracia</surname><given-names>A.</given-names></name>
<name><surname>Ong</surname><given-names>H.L.</given-names></name>
<name><surname>Lagua</surname><given-names>F.M.</given-names></name>
<name><surname>Alea</surname><given-names>G.</given-names></name>
</person-group><article-title>Chemical reactivity and bioactivity properties of pyrazinamide analogs of acetylsalicylic acid and salicylic acid using conceptual density functional theory</article-title><source>Heliyon</source><year>2020</year><volume>6</volume><fpage>e04239</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e04239</pub-id><pub-id pub-id-type="pmid">32613118</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00211"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Z.-F.</given-names></name>
<name><surname>Li</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>S.-Q.</given-names></name>
</person-group><article-title>Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis</article-title><source>Chemotherapy</source><year>2007</year><volume>53</volume><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1159/000107723</pub-id><pub-id pub-id-type="pmid">17785970</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00211"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hall II</surname><given-names>R.G.</given-names></name>
<name><surname>Leff</surname><given-names>R.D.</given-names></name>
<name><surname>Gumbo</surname><given-names>T.</given-names></name>
</person-group><article-title>Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2009</year><volume>29</volume><fpage>1468</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1592/phco.29.12.1468</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-18-00211"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alshaikh</surname><given-names>R.A.</given-names></name>
<name><surname>Essa</surname><given-names>E.A.</given-names></name>
<name><surname>El Maghraby</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Eutexia for enhanced dissolution rate and anti-inflammatory activity of nonsteroidal anti-inflammatory agents: Caffeine as a melting point modulator</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>563</volume><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.04.024</pub-id><pub-id pub-id-type="pmid">30978486</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00211"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>R.P.</given-names></name>
<name><surname>de Carvalho</surname><given-names>A.C.S.</given-names></name>
<name><surname>Ekawa</surname><given-names>B.</given-names></name>
<name><surname>do Nascimento</surname><given-names>A.L.S.C.</given-names></name>
<name><surname>Pironi</surname><given-names>A.M.</given-names></name>
<name><surname>Chorilli</surname><given-names>M.</given-names></name>
<name><surname>Caires</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Synthesis and characterization of meloxicam eutectics with mandelic acid and saccharin for enhanced solubility</article-title><source>Drug Dev. Ind. Pharm.</source><year>2020</year><volume>46</volume><fpage>1092</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1080/03639045.2020.1775633</pub-id><pub-id pub-id-type="pmid">32475190</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00211"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Seo</surname><given-names>H.J.</given-names></name>
<name><surname>Ha</surname><given-names>E.-S.</given-names></name>
<name><surname>Hong</surname><given-names>S.-h.</given-names></name>
<name><surname>Kim</surname><given-names>J.-S.</given-names></name>
<name><surname>Kim</surname><given-names>M.-S.</given-names></name>
<name><surname>Hwang</surname><given-names>S.-J.</given-names></name>
</person-group><article-title>Preparation and characterization of glimepiride eutectic mixture with l-arginine for improvement of dissolution rate</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>581</volume><fpage>119288</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119288</pub-id><pub-id pub-id-type="pmid">32243966</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00211"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rai</surname><given-names>U.S.</given-names></name>
<name><surname>Rai</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Physical chemistry of the organic analog of metal&#x02013;metal eutectic and monotectic alloys</article-title><source>J. Cryst. Growth</source><year>1998</year><volume>191</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/S0022-0248(98)00105-5</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-18-00211"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Law</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Schmitt</surname><given-names>E.A.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.</given-names></name>
<name><surname>Krill</surname><given-names>S.L.</given-names></name>
<name><surname>Fort</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Properties of Rapidly Dissolving Eutectic Mixtures of Poly(ethylene glycol) and Fenofibrate:The Eutectic Microstructure</article-title><source>J. Pharm. Sci.</source><year>2003</year><volume>92</volume><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1002/jps.10324</pub-id><pub-id pub-id-type="pmid">12587112</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00211"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaturvedi</surname><given-names>K.</given-names></name>
<name><surname>Shah</surname><given-names>H.S.</given-names></name>
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Dave</surname><given-names>R.</given-names></name>
<name><surname>Morris</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Contribution of Crystal Lattice Energy on the Dissolution Behavior of Eutectic Solid Dispersions</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>9690</fpage><lpage>9701</lpage><pub-id pub-id-type="doi">10.1021/acsomega.9b03886</pub-id><pub-id pub-id-type="pmid">32391455</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00211"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kant</surname><given-names>S.</given-names></name>
<name><surname>Rai</surname><given-names>U.S.</given-names></name>
<name><surname>Rai</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Thermal and physico-chemical studies on binary organic eutectic systems: 4-Aminoacetophenone with benzoin and 4-nitrophenol</article-title><source>J. Therm. Anal. Calorim.</source><year>2012</year><volume>110</volume><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1007/s10973-012-2537-6</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-18-00211"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reddi</surname><given-names>R.S.B.</given-names></name>
<name><surname>Satuluri</surname><given-names>V.S.A.K.</given-names></name>
<name><surname>Rai</surname><given-names>U.S.</given-names></name>
<name><surname>Rai</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Thermal, physicochemical and microstructural studies of binary organic eutectic systems</article-title><source>J. Therm. Anal. Calorim.</source><year>2012</year><volume>107</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s10973-011-1478-9</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-18-00211"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goud</surname><given-names>N.R.</given-names></name>
<name><surname>Suresh</surname><given-names>K.</given-names></name>
<name><surname>Sanphui</surname><given-names>P.</given-names></name>
<name><surname>Nangia</surname><given-names>A.</given-names></name>
</person-group><article-title>Fast dissolving eutectic compositions of curcumin</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>439</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.09.045</pub-id><pub-id pub-id-type="pmid">23041131</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00211"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Yamano</surname><given-names>A.</given-names></name>
<name><surname>Sato</surname><given-names>T.</given-names></name>
<name><surname>Ferrara</surname><given-names>J.D.</given-names></name>
<name><surname>White</surname><given-names>F.J.</given-names></name>
<name><surname>Meyer</surname><given-names>M.</given-names></name>
</person-group><article-title>&#x0201c;What is This?&#x0201d; A Structure Analysis Tool for Rapid and Automated Solution of Small Molecule Structures</article-title><source>J. Chem. Crystallogr.</source><year>2021</year><volume>51</volume><fpage>438</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1007/s10870-020-00867-w</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-18-00211"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takaki</surname><given-names>Y.</given-names></name>
<name><surname>Sasada</surname><given-names>Y.</given-names></name>
<name><surname>Watanabe</surname><given-names>T.</given-names></name>
</person-group><article-title>The crystal structure of [alpha]-pyrazinamide</article-title><source>Acta Crystallogr.</source><year>1960</year><volume>13</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1107/S0365110X60001680</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-18-00211"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castro</surname><given-names>R.A.</given-names></name>
<name><surname>Maria</surname><given-names>T.M.</given-names></name>
<name><surname>&#x000c9;vora</surname><given-names>A.O.</given-names></name>
<name><surname>Feiteira</surname><given-names>J.C.</given-names></name>
<name><surname>Silva</surname><given-names>M.R.</given-names></name>
<name><surname>Beja</surname><given-names>A.M.</given-names></name>
<name><surname>Canotilho</surname><given-names>J.</given-names></name>
<name><surname>Eus&#x000e9;bio</surname><given-names>M.E.S.</given-names></name>
</person-group><article-title>A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships</article-title><source>Cryst. Growth. Des.</source><year>2010</year><volume>10</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1021/cg900890n</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-18-00211"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Nandi</surname><given-names>R.</given-names></name>
<name><surname>Gangopadhyay</surname><given-names>D.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Temperature dependent polymorphism of pyrazinamide: An in situ Raman and DFT study</article-title><source>Spectroc. Acta Pt. A-Mol. Biomol.</source><year>2018</year><volume>190</volume><fpage>177</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.saa.2017.09.016</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-18-00211"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi&#x0015f;</surname><given-names>V.</given-names></name>
<name><surname>P&#x000ee;rn&#x00103;u</surname><given-names>A.</given-names></name>
<name><surname>Jurc&#x00103;</surname><given-names>T.</given-names></name>
<name><surname>Vasilescu</surname><given-names>M.</given-names></name>
<name><surname>Simon</surname><given-names>S.</given-names></name>
<name><surname>Cozar</surname><given-names>O.</given-names></name>
<name><surname>David</surname><given-names>L.</given-names></name>
</person-group><article-title>Experimental and DFT study of pyrazinamide</article-title><source>Chem. Phys.</source><year>2005</year><volume>316</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.chemphys.2005.05.004</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-18-00211"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raman</surname><given-names>A.P.S.</given-names></name>
<name><surname>Singh</surname><given-names>M.B.</given-names></name>
<name><surname>Chaudhary</surname><given-names>M.</given-names></name>
<name><surname>Bahdur</surname><given-names>I.</given-names></name>
<name><surname>Jain</surname><given-names>P.</given-names></name>
<name><surname>Kaushik</surname><given-names>N.</given-names></name>
<name><surname>Choi</surname><given-names>E.H.</given-names></name>
<name><surname>Kaushik</surname><given-names>N.K.</given-names></name>
<name><surname>Lal</surname><given-names>A.A.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
</person-group><article-title>DFT calculations, molecular docking and SAR investigation for the formation of eutectic mixture using thiourea and salicylic acid</article-title><source>J. Mol. Liq.</source><year>2022</year><volume>362</volume><fpage>119650</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2022.119650</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-18-00211"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Kumari</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Bahadur</surname><given-names>I.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
</person-group><article-title>Noscapine anticancer drug designed with ionic liquids to enhance solubility: DFT and ADME approach</article-title><source>J. Mol. Liq.</source><year>2021</year><volume>325</volume><fpage>115159</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2020.115159</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-18-00211"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Araya-Sibaja</surname><given-names>A.M.</given-names></name>
<name><surname>Vega-Baudrit</surname><given-names>J.R.</given-names></name>
<name><surname>Guill&#x000e9;n-Gir&#x000f3;n</surname><given-names>T.</given-names></name>
<name><surname>Navarro-Hoyos</surname><given-names>M.</given-names></name>
<name><surname>Cuffini</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Drug Solubility Enhancement through the Preparation of Multicomponent Organic Materials: Eutectics of Lovastatin with Carboxylic Acids</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11030112</pub-id><pub-id pub-id-type="pmid">30857331</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00211"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nataraj</surname><given-names>A.</given-names></name>
<name><surname>Balachandran</surname><given-names>V.</given-names></name>
<name><surname>Karthick</surname><given-names>T.</given-names></name>
</person-group><article-title>Molecular orbital studies (hardness, chemical potential, electrophilicity, and first electron excitation), vibrational investigation and theoretical NBO analysis of 2-hydroxy-5-bromobenzaldehyde by density functional method</article-title><source>J. Mol. Struct.</source><year>2013</year><volume>1031</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2012.09.047</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-18-00211"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miar</surname><given-names>M.</given-names></name>
<name><surname>Shiroudi</surname><given-names>A.</given-names></name>
<name><surname>Pourshamsian</surname><given-names>K.</given-names></name>
<name><surname>Oliaey</surname><given-names>A.R.</given-names></name>
<name><surname>Hatamjafari</surname><given-names>F.</given-names></name>
</person-group><article-title>Theoretical investigations on the HOMO&#x02013;LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo[d]thiazole-2(3H)-imine and its para-substituted derivatives: Solvent and substituent effects</article-title><source>J. Chem. Res.</source><year>2020</year><volume>45</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1177/1747519820932091</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-18-00211"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Proft</surname><given-names>F.</given-names></name>
<name><surname>Sablon</surname><given-names>N.</given-names></name>
<name><surname>Tozer</surname><given-names>D.J.</given-names></name>
<name><surname>Geerlings</surname><given-names>P.</given-names></name>
</person-group><article-title>Calculation of negative electron affinity and aqueous anion hardness using Kohn&#x02013;Sham HOMO and LUMO energies</article-title><source>Faraday Discuss.</source><year>2007</year><volume>135</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1039/B605302P</pub-id><pub-id pub-id-type="pmid">17328427</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00211"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edim</surname><given-names>M.M.</given-names></name>
<name><surname>Louis</surname><given-names>H.</given-names></name>
<name><surname>Bisong</surname><given-names>E.A.</given-names></name>
<name><surname>Chioma</surname><given-names>A.G.</given-names></name>
<name><surname>Enudi</surname><given-names>O.C.</given-names></name>
<name><surname>Unimuke</surname><given-names>T.O.</given-names></name>
<name><surname>Bassey</surname><given-names>A.B.</given-names></name>
<name><surname>Prince</surname><given-names>D.</given-names></name>
<name><surname>Sam</surname><given-names>Q.O.</given-names></name>
<name><surname>Ubana</surname><given-names>E.I.</given-names></name>
<etal/>
</person-group><article-title>Electronic structure theory study of the reactivity and structural molecular properties of halo-substituted (F, Cl, Br) and heteroatom (N, O, S) doped cyclobutane</article-title><source>Phys. Sci. Rev.</source><year>2023</year><volume>8</volume><fpage>715</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1515/psr-2020-0138</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-18-00211"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Malah</surname><given-names>K.I.</given-names></name>
</person-group><article-title>Aqueous solubility of a simple (single-carbon) organic molecule as a function of its size &#x00026; dipole moment</article-title><source>J. Mol. Model.</source><year>2011</year><volume>17</volume><fpage>1029</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1007/s00894-010-0800-y</pub-id><pub-id pub-id-type="pmid">20652341</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00211"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
</person-group><article-title>Multiwfn: A multifunctional wavefunction analyzer</article-title><source>J. Comput. Chem.</source><year>2012</year><volume>33</volume><fpage>580</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1002/jcc.22885</pub-id><pub-id pub-id-type="pmid">22162017</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00211"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willetts</surname><given-names>S.</given-names></name>
<name><surname>Foley</surname><given-names>D.W.</given-names></name>
</person-group><article-title>True or false? Challenges and recent highlights in the development of aspirin prodrugs</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>192</volume><fpage>112200</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112200</pub-id><pub-id pub-id-type="pmid">32163816</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00211"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolezal</surname><given-names>M.</given-names></name>
<name><surname>Kesetovic</surname><given-names>D.</given-names></name>
<name><surname>Zitko</surname><given-names>J.</given-names></name>
</person-group><article-title>Antimycobacterial Evaluation of Pyrazinoic Acid Reversible Derivatives</article-title><source>Curr. Pharm. Design</source><year>2011</year><volume>17</volume><fpage>3506</fpage><lpage>3514</lpage><pub-id pub-id-type="doi">10.2174/138161211798194477</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-18-00211"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Callahan</surname><given-names>J.C.</given-names></name>
<name><surname>Cleary</surname><given-names>G.W.</given-names></name>
<name><surname>Elefant</surname><given-names>M.</given-names></name>
<name><surname>Kaplan</surname><given-names>G.</given-names></name>
<name><surname>Kensler</surname><given-names>T.</given-names></name>
<name><surname>Nash</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Equilibrium Moisture Content of Pharmaceutical Excipients</article-title><source>Drug Dev. Ind. Pharm.</source><year>1982</year><volume>8</volume><fpage>355</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.3109/03639048209022105</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-18-00211"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>T.S.</given-names></name>
<name><surname>Thakuria</surname><given-names>R.</given-names></name>
</person-group><article-title>Crystalline Multicomponent Solids: An Alternative for Addressing the Hygroscopicity Issue in Pharmaceutical Materials</article-title><source>Cryst. Growth. Des.</source><year>2020</year><volume>20</volume><fpage>6245</fpage><lpage>6265</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.0c00654</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-18-00211"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>Y.-H.</given-names></name>
<name><surname>Sun</surname><given-names>B.-W.</given-names></name>
</person-group><article-title>Pharmaceutical co-crystals of pyrazinecarboxamide (PZA) with various carboxylic acids: Crystallography, hirshfeld surfaces, and dissolution study</article-title><source>Cryst. Growth. Des.</source><year>2013</year><volume>13</volume><fpage>2098</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1021/cg400167w</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-18-00211"><label>75.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Felder</surname><given-names>E.</given-names></name>
<name><surname>Pitre</surname><given-names>D.</given-names></name>
</person-group><article-title>Pyrazinamide</article-title><source>Analytical Profiles of Drug Substances</source><person-group person-group-type="editor">
<name><surname>Florey</surname><given-names>K.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>1983</year><volume>Volume 12</volume><fpage>433</fpage><lpage>462</lpage></element-citation></ref><ref id="B76-pharmaceuticals-18-00211"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rowland</surname><given-names>M.</given-names></name>
<name><surname>Riegelman</surname><given-names>S.</given-names></name>
<name><surname>Harris</surname><given-names>P.A.</given-names></name>
<name><surname>Sholkoff</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Absorption Kinetics of Aspirin in Man follow Oral Administration of an Aqueous Solution</article-title><source>J. Pharm. Sci.</source><year>1972</year><volume>61</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1002/jps.2600610312</pub-id><pub-id pub-id-type="pmid">5013373</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00211"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berthold-Pluta</surname><given-names>A.</given-names></name>
<name><surname>Pluta</surname><given-names>A.</given-names></name>
<name><surname>Garbowska</surname><given-names>M.</given-names></name>
</person-group><article-title>The effect of selected factors on the survival of Bacillus cereus in the human gastrointestinal tract</article-title><source>Microb. Pathog.</source><year>2015</year><volume>82</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2015.03.015</pub-id><pub-id pub-id-type="pmid">25794697</pub-id>
</element-citation></ref><ref id="B78-pharmaceuticals-18-00211"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dressman</surname><given-names>J.B.</given-names></name>
<name><surname>Amidon</surname><given-names>G.L.</given-names></name>
<name><surname>Reppas</surname><given-names>C.</given-names></name>
<name><surname>Shah</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms</article-title><source>Pharm. Res.</source><year>1998</year><volume>15</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1023/A:1011984216775</pub-id><pub-id pub-id-type="pmid">9487541</pub-id>
</element-citation></ref><ref id="B79-pharmaceuticals-18-00211"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>A.H.</given-names></name>
<name><surname>Gibaldi</surname><given-names>M.</given-names></name>
<name><surname>Kanig</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Increasing Dissolution Rates and Gastrointestinal Absorption of Drugs Via Solid Solutions and Eutectic Mixtures I: Theoretical Considerations and Discussion of the Literature</article-title><source>J. Pharm. Sci.</source><year>1965</year><volume>54</volume><fpage>1145</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1002/jps.2600540810</pub-id><pub-id pub-id-type="pmid">5882218</pub-id>
</element-citation></ref><ref id="B80-pharmaceuticals-18-00211"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>B.</given-names></name>
<name><surname>Gunnam</surname><given-names>A.</given-names></name>
<name><surname>Thipparaboina</surname><given-names>R.</given-names></name>
<name><surname>Nangia</surname><given-names>A.K.</given-names></name>
<name><surname>Shastri</surname><given-names>N.R.</given-names></name>
</person-group><article-title>Hepatoprotective cocrystals of isoniazid: Synthesis, solid state characterization, and hepatotoxicity studies</article-title><source>Cryst. Growth. Des.</source><year>2019</year><volume>19</volume><fpage>5161</fpage><lpage>5172</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.9b00541</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-18-00211"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>P.</given-names></name>
<name><surname>Sousa Lobo</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Modeling and comparison of dissolution profiles</article-title><source>Eur. J. Pharm. Sci.</source><year>2001</year><volume>13</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(01)00095-1</pub-id><pub-id pub-id-type="pmid">11297896</pub-id>
</element-citation></ref><ref id="B82-pharmaceuticals-18-00211"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>E.C.H.</given-names></name>
<name><surname>Johnson</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Prediction of Eutectic Temperatures, Compositions and Phase Diagrams for Binary Mesophase Systemst</article-title><source>Mol. Cryst. Liquid Cryst.</source><year>1974</year><volume>27</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1080/15421407408083122</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-18-00211"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chai</surname><given-names>J.-D.</given-names></name>
<name><surname>Head-Gordon</surname><given-names>M.</given-names></name>
</person-group><article-title>Long-range corrected hybrid density functionals with damped atom&#x02013;atom dispersion corrections</article-title><source>Phys. Chem. Chem. Phys.</source><year>2008</year><volume>10</volume><fpage>6615</fpage><lpage>6620</lpage><pub-id pub-id-type="doi">10.1039/b810189b</pub-id><pub-id pub-id-type="pmid">18989472</pub-id>
</element-citation></ref><ref id="B84-pharmaceuticals-18-00211"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ditchfield</surname><given-names>R.</given-names></name>
<name><surname>Hehre</surname><given-names>W.J.</given-names></name>
<name><surname>Pople</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Self-consistent molecular-orbital methods. IX. An extended Gaussian-type basis for molecular-orbital studies of organic molecules</article-title><source>J. Chem. Phys.</source><year>1971</year><volume>54</volume><fpage>724</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1063/1.1674902</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-18-00211"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adamo</surname><given-names>C.</given-names></name>
<name><surname>Barone</surname><given-names>V.</given-names></name>
</person-group><article-title>Exchange functionals with improved long-range behavior and adiabatic connection methods without adjustable parameters: The m PW and m PW1PW models</article-title><source>J. Chem. Phys.</source><year>1998</year><volume>108</volume><fpage>664</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1063/1.475428</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-18-00211"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanwell</surname><given-names>M.D.</given-names></name>
<name><surname>Curtis</surname><given-names>D.E.</given-names></name>
<name><surname>Lonie</surname><given-names>D.C.</given-names></name>
<name><surname>Vandermeersch</surname><given-names>T.</given-names></name>
<name><surname>Zurek</surname><given-names>E.</given-names></name>
<name><surname>Hutchison</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Avogadro: An advanced semantic chemical editor, visualization, and analysis platform</article-title><source>J. Cheminform.</source><year>2012</year><volume>4</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-4-17</pub-id><pub-id pub-id-type="pmid">22889332</pub-id>
</element-citation></ref><ref id="B87-pharmaceuticals-18-00211"><label>87.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Frisch</surname><given-names>M.</given-names></name>
<name><surname>Trucks</surname><given-names>G.</given-names></name>
<name><surname>Schlegel</surname><given-names>H.</given-names></name>
<name><surname>Scuseria</surname><given-names>G.</given-names></name>
<name><surname>Robb</surname><given-names>M.</given-names></name>
<name><surname>Cheeseman</surname><given-names>J.</given-names></name>
<name><surname>Scalmani</surname><given-names>G.</given-names></name>
<name><surname>Barone</surname><given-names>V.</given-names></name>
<name><surname>Petersson</surname><given-names>G.</given-names></name>
<name><surname>Nakatsuji</surname><given-names>H.</given-names></name>
</person-group><article-title>Gaussian 16</article-title><source>Revision A. 03</source><publisher-name>Gaussian. Inc.</publisher-name><publisher-loc>Wallingford, CT, USA</publisher-loc><year>2016</year><volume>Volume 3</volume></element-citation></ref><ref id="B88-pharmaceuticals-18-00211"><label>88.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Andrienko</surname><given-names>G.</given-names></name>
</person-group><article-title>Chemcraft-Graphical Software for Visualization of Quantum Chemistry Computations</article-title><year>2010</year><comment>Available online: <ext-link xlink:href="https://www.chemcraftprog.com" ext-link-type="uri">https://www.chemcraftprog.com</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-25">(accessed on 25 August 2024)</date-in-citation></element-citation></ref><ref id="B89-pharmaceuticals-18-00211"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>Y.</given-names></name>
<name><surname>Ito</surname><given-names>S.</given-names></name>
<name><surname>Itai</surname><given-names>S.</given-names></name>
<name><surname>Yamamoto</surname><given-names>K.</given-names></name>
</person-group><article-title>Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate</article-title><source>Int. J. Pharm.</source><year>2000</year><volume>193</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(99)00315-4</pub-id><pub-id pub-id-type="pmid">10606776</pub-id>
</element-citation></ref><ref id="B90-pharmaceuticals-18-00211"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murdande</surname><given-names>S.B.</given-names></name>
<name><surname>Pikal</surname><given-names>M.J.</given-names></name>
<name><surname>Shanker</surname><given-names>R.M.</given-names></name>
<name><surname>Bogner</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement</article-title><source>Pharm. Dev. Technol.</source><year>2011</year><volume>16</volume><fpage>187</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.3109/10837451003774377</pub-id><pub-id pub-id-type="pmid">20429826</pub-id>
</element-citation></ref><ref id="B91-pharmaceuticals-18-00211"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melo</surname><given-names>K.J.C.</given-names></name>
<name><surname>Henostroza</surname><given-names>M.A.B.</given-names></name>
<name><surname>L&#x000f6;benberg</surname><given-names>R.</given-names></name>
<name><surname>Bou-Chacra</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis</article-title><source>Mater. Sci. Eng. C</source><year>2020</year><volume>112</volume><fpage>110895</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.110895</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-18-00211"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>P.H.</given-names></name>
<name><surname>Belgamwar</surname><given-names>V.S.</given-names></name>
<name><surname>Patil</surname><given-names>P.R.</given-names></name>
<name><surname>Surana</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Enhancement of solubility and dissolution rate of poorly water soluble raloxifene using microwave induced fusion method</article-title><source>Braz. J. Pharm. Sci.</source><year>2013</year><volume>49</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1590/S1984-82502013000300019</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-18-00211"><label>93.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Commision</surname><given-names>B.P.</given-names></name>
</person-group><source>British Pharmacopoeia</source><publisher-name>The Stationery Office</publisher-name><publisher-loc>London, UK</publisher-loc><year>2009</year></element-citation></ref><ref id="B94-pharmaceuticals-18-00211"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huo</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Zou</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Yao</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
</person-group><article-title>DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9185-1</pub-id><pub-id pub-id-type="pmid">20373062</pub-id>
</element-citation></ref><ref id="B95-pharmaceuticals-18-00211"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bharate</surname><given-names>S.S.</given-names></name>
<name><surname>Bharate</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Spectrophotometric and Chromatographic determination of acetylsalicylic acid and Caffeine in pure and in tablet dosage form</article-title><source>J. Adv. Sci. Res.</source><year>2012</year><volume>3</volume><fpage>73</fpage><lpage>81</lpage></element-citation></ref><ref id="B96-pharmaceuticals-18-00211"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khawas</surname><given-names>S.</given-names></name>
<name><surname>Parui</surname><given-names>S.</given-names></name>
<name><surname>Dey</surname><given-names>S.</given-names></name>
<name><surname>Mandal</surname><given-names>S.</given-names></name>
<name><surname>Sarkar</surname><given-names>S.</given-names></name>
</person-group><article-title>Simultaneous Spectrophotometric Estimation of Rifampicin, Isoniazid and Pyrazinamide in their Pharmaceutical Dosage Form</article-title><source>Asian J. Res. Chem.</source><year>2020</year><volume>13</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.5958/0974-4150.2020.00024.3</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-18-00211"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinho</surname><given-names>L.A.G.</given-names></name>
<name><surname>S&#x000e1;-Barreto</surname><given-names>L.C.L.</given-names></name>
<name><surname>Infante</surname><given-names>C.M.C.</given-names></name>
<name><surname>Cunha-Filho</surname><given-names>M.S.S.</given-names></name>
</person-group><article-title>Simultaneous determination of benznidazole and itraconazole using spectrophotometry applied to the analysis of mixture: A tool for quality control in the development of formulations</article-title><source>Spectroc. Acta Pt. A-Mol. Biomol.</source><year>2016</year><volume>159</volume><fpage>48</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.saa.2016.01.040</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-18-00211"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrews</surname><given-names>G.P.</given-names></name>
<name><surname>Qian</surname><given-names>K.</given-names></name>
<name><surname>Jacobs</surname><given-names>E.</given-names></name>
<name><surname>Jones</surname><given-names>D.S.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
</person-group><article-title>High drug loading nanosized amorphous solid dispersion (NASD) with enhanced in vitro solubility and permeability: Benchmarking conventional ASD</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>632</volume><fpage>122551</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122551</pub-id><pub-id pub-id-type="pmid">36581107</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00211-f001"><label>Figure 1</label><caption><p>DSC curves of ASA<sub>LAG</sub>, PZA<sub>LAG</sub>, and mixtures prepared by the liquid-assisted grinding (LAG) method, with 0.17, 0.20, 0.25, 0.33, 0.50, 0.67, 0.75, 0.80, and 0.83 molar ratios of ASA.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f002"><label>Figure 2</label><caption><p>Theorical and experimental binary diagram (<bold>a</bold>) and Tammann&#x02019;s triangle (<bold>b</bold>) of ASA, PZA, and mixtures prepared by the LAG method with ASA molar ratios of 0.17, 0.20, 0.25, 0.33, 0.50, 0.67, 0.75, 0.80, and 0.83.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f003"><label>Figure 3</label><caption><p>PXRD patterns of ASA<sub>LAG</sub>, PZA<sub>LAG</sub> and ASA-PZA mixtures.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f004"><label>Figure 4</label><caption><p>IR spectra of ground acetylsalicylic acid (ASA<sub>LAG</sub>), ground pyrazinamide (PZA<sub>LAG</sub>), DDEM (ASA-PZA (2:1)) and its PM (ASA-PZA (2:1)<sub>PM</sub>).</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f005"><label>Figure 5</label><caption><p>Raman spectra of ASA<sub>LAG</sub> (green), PZA<sub>LAG</sub> (black), DDEM (ASA-PZA (2:1)) (blue), and PM (ASA-PZA (2:1)<sub>PM</sub>) (red); Spectral region: (<bold>a</bold>) 70-200 cm<sup>&#x02212;1</sup>; (<bold>b</bold>) 200-1800 cm<sup>&#x02212;1</sup>; and (<bold>c</bold>) 2800-3600 cm<sup>&#x02212;1</sup>.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f006"><label>Figure 6</label><caption><p>HOMO and LUMO for ASA (<bold>left</bold>) and PZA (<bold>right</bold>) in vacuum, obtained from calculations employing the DFT functional <italic toggle="yes">&#x003c9;</italic>B97X-D and 6-311G++(d,p) basis set.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f007"><label>Figure 7</label><caption><p>Electrostatic potential map for ASA (<bold>a</bold>) and PZA (<bold>b</bold>) in vacuum, obtained from calculations employing the DFT functional <italic toggle="yes">&#x003c9;</italic>B97X-D and 6-311G++(d,p) basis set.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f008"><label>Figure 8</label><caption><p>Hygroscopicity test of ASA, PZA, DDEM (ASA-PZA (2:1)), and PM (ASA-PZA (2:1)<sub>PM</sub>) at 1, 2, 3, 4, 5, 10, 15, and 30 days (n = 3).</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g008" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00211-f009"><label>Figure 9</label><caption><p>Dissolution study in 6.8 pH buffer of the free drugs and included in the physical mixture and drug&#x02013;drug eutectic solid.</p></caption><graphic xlink:href="pharmaceuticals-18-00211-g009" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00211-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00211-t001_Table 1</object-id><label>Table 1</label><caption><p>Experimental values of melting temperatures, enthalpy of fusion, and entropy of fusion of pure compounds and drug&#x02013;drug eutectic mixtures (DDEMs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T<italic toggle="yes"><sub>fus</sub></italic> (&#x000b0;C)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T<italic toggle="yes"><sub>fus</sub></italic> (K)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;H<italic toggle="yes"><sub>fus</sub></italic> (kJ.mol<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;S<italic toggle="yes"><sub>fus</sub></italic> (J/(mol.K)<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;S<italic toggle="yes"><sub>fus</sub></italic><sup>0</sup> (&#x00394;<italic toggle="yes"><sub>fus</sub></italic>S/R)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">ASA<sub>LAG</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">140.8</td><td align="center" valign="middle" rowspan="1" colspan="1">413.9</td><td align="center" valign="middle" rowspan="1" colspan="1">41.33</td><td align="center" valign="middle" rowspan="1" colspan="1">99.85</td><td align="center" valign="middle" rowspan="1" colspan="1">12.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PZA<sub>LAG</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">189.5</td><td align="center" valign="middle" rowspan="1" colspan="1">462.6</td><td align="center" valign="middle" rowspan="1" colspan="1">26.69</td><td align="center" valign="middle" rowspan="1" colspan="1">57.69</td><td align="center" valign="middle" rowspan="1" colspan="1">6.94</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DDEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">387.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">308.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.05</td></tr></tbody></table><table-wrap-foot><fn><p>The gas constant R = 8.31447 J.mol<sup>&#x02212;1</sup>.K<sup>&#x02212;1</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00211-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00211-t002_Table 2</object-id><label>Table 2</label><caption><p>Chemical reactivity indices for acetylsalicylic acid (ASA<sub>vac</sub>) and pyrazinamide (PZA<sub>vac</sub>) in vacuum.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IE <italic toggle="yes"><sup>a</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EA <italic toggle="yes"><sup>a</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HLG</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003b7; <italic toggle="yes"><sup>a</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003c3; <italic toggle="yes"><sup>b</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003c7; <italic toggle="yes"><sup>a</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003bc; <italic toggle="yes"><sup>a</sup></italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; <italic toggle="yes"><sup>a</sup></italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">ASA<sub>vac</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">9.33</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">9.36</td><td align="center" valign="middle" rowspan="1" colspan="1">4.68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" rowspan="1" colspan="1">4.65</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.65</td><td align="center" valign="middle" rowspan="1" colspan="1">2.31</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PZA<sub>vac</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.67</td></tr></tbody></table><table-wrap-foot><fn><p>IE = ionization energy; EA = electronic affinity; HLG = HOMO-LUMO gap; <italic toggle="yes">&#x003b7;</italic> = hardness; <italic toggle="yes">&#x003c3;</italic> = softness; <italic toggle="yes">&#x003c7;</italic> = electronegativity; <italic toggle="yes">&#x003bc;</italic> = chemical potential; <italic toggle="yes">&#x003c9;</italic> = global electrophilicity index; <italic toggle="yes"><sup>a</sup></italic> values in eV; <italic toggle="yes"><sup>b</sup></italic> values in eV<sup>&#x02212;1</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00211-t003"><object-id pub-id-type="pii">pharmaceuticals-18-00211-t003_Table 3</object-id><label>Table 3</label><caption><p>Solubility study of ASA, PZA, the ASA, and PZA present in the physical mixture ASA-PZA (2:1)<sub>PM</sub>, and the drug&#x02013;drug eutectic mixture ASA-PZA (2:1).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solubility of <break/>ASA (mg.mL<sup>&#x02212;1</sup>) <sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RSD (%) <sup>b</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solubility of PZA<break/>(mg.mL<sup>&#x02212;1</sup>) <sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RSD (%) <sup>b</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">ASA</td><td align="center" valign="middle" rowspan="1" colspan="1">16.1 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PZA</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">22.6 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ASA-PZA (2:1)<sub>PM</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">19.1 &#x000b1; 0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">31.2 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASA-PZA (2:1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.0 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.0 &#x000b1; 1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> All values are mean (n = 3) &#x000b1; SD, standard deviation (SD); <sup>b</sup> relative standard deviation (RSD). The pH of the medium during the entire solubility experiment was constant at about pH &#x02248; 6.80 (pH after solubility: PZA = 6.80 &#x000b1; 0.02; ASA = 6.79 &#x000b1; 0.03; ASA-PZA (2:1)<sub>PM</sub> = 6.76 &#x000b1; 0.02; DDEM = 6.75 &#x000b1; 0.05).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00211-t004"><object-id pub-id-type="pii">pharmaceuticals-18-00211-t004_Table 4</object-id><label>Table 4</label><caption><p>Dissolution parameters of ASA, PZA, the drug&#x02013;drug eutectic solid ASA-PZA (2:1), and the physical mixture ASA-PZA (2:1)<sub>PM</sub>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ASA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ASA in<break/>PM</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ASA in<break/>DDEM</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PZA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PZA in PM</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PZA in DDEM</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Q</td><td align="center" valign="middle" rowspan="1" colspan="1">85.1 </td><td align="center" valign="middle" rowspan="1" colspan="1">81.5</td><td align="center" valign="middle" rowspan="1" colspan="1">95.9</td><td align="center" valign="middle" rowspan="1" colspan="1">97.7</td><td align="center" valign="middle" rowspan="1" colspan="1">96.4</td><td align="center" valign="middle" rowspan="1" colspan="1">97.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.104</td><td align="center" valign="middle" rowspan="1" colspan="1">0.100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.097</td><td align="center" valign="middle" rowspan="1" colspan="1">0.127</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">0.125</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>2</sub>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.69</td></tr></tbody></table><table-wrap-foot><fn><p>PM: physical mixture; DDEM: drug&#x02013;drug eutectic mixture; Q (10 min): % drug release; DE (10 min): dissolution efficiency in 10 min; <italic toggle="yes">f</italic><sub>2</sub>: similarity factor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00211-t005"><object-id pub-id-type="pii">pharmaceuticals-18-00211-t005_Table 5</object-id><label>Table 5</label><caption><p>Reactivity descriptors and corresponding equations derived from frontier molecular orbital energies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Property (Abbreviation)</bold>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Math Expression</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ionization energy (IE)</td><td align="center" valign="middle" rowspan="1" colspan="1">IE = &#x02212;E<sub>HOMO</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">(4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Electronic affinity (EA)</td><td align="center" valign="middle" rowspan="1" colspan="1">EA <inline-formula><mml:math id="mm25" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mo>=</mml:mo></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> &#x02212;E<sub>LUMO</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">(5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HOMO-LUMO gap (HLG)</td><td align="center" valign="middle" rowspan="1" colspan="1">HLG = E<sub>LUMO</sub> &#x02212; E<sub>HOMO</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">(6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hardness (&#x003b7;)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm26" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x003b7;</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>O</mml:mi><mml:mi>M</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">(7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Softness (S)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm27" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003b7;</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">(8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Electronegativity (<italic toggle="yes">&#x003c7;</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm28" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#x003c7;</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>U</mml:mi><mml:mi>M</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>O</mml:mi><mml:mi>M</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">(9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chemical potential (&#x000b5;)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;&#x000b5; = <italic toggle="yes">&#x003c7;</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">(10)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrophilicity (&#x003c9;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm29" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#x003c9;</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">&#x000b5;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003b7;</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11)</td></tr></tbody></table></table-wrap></floats-group></article>